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The blood glucose and insulin responses to acute maximal and submaximal 
aerobic exercise are well characterized (Marliss & Vranic, 2002), though our 
understanding of the molecular mechanisms effecting improved insulin sensitivity 
following acute exercise remains incomplete.  Apelin has been reported to enhance 
glucose uptake and insulin sensitivity in vitro and in vivo (Dray et al., 2010).  Apelin, 
therefore, merits examination as a potential regulator of the acute enhancement of insulin 
sensitivity in vivo.  PURPOSE: To investigate apelin’s response to acute bouts of 
maximal and submaximal aerobic exercise, so as to elucidate apelin’s influence on 
glucose homeostasis and insulin sensitivity.  METHODS: Twelve (22.8 ± 2.9 yrs) 
apparently healthy male (n=7) and female (n=5) subjects completed maximal (VO2max) 
and submaximal (70-75% VO2max) aerobic treadmill tests, as well as a 54g glucose 
challenge (GC), each separated by at least 3 days but not more than 14 days.  Blood was 
sampled four times (Pre-, Post-, 1 hr post- and 24 hrs post-treatment) and assessed 
immediately for hematocrit and blood glucose and assayed for plasma apelin and plasma 
insulin.  Insulin resistance was determined via HOMA-IR index.  RESULTS: No main 
effect existed for apelin by condition (p=0.324) or by time (p=0.633).  Blood glucose and 
plasma insulin were significantly elevated following VO2max and GC, but not following 
submaximal exercise.  Insulin resistance, as measured via HOMA-IR score, was 
	  
significantly improved at one-hour post-submaximal exercise.  Resting plasma apelin was 
significantly correlated with plasma insulin (R=0.702, p=0.011), as well as with resting 
HOMA-IR score (R=0.738, p=0.006).  Following submaximal exercise, plasma apelin 
was significantly correlated with HOMA-IR score (R=0.672, p=0.017).  
CONCLUSION:  Though plasma apelin was not significantly altered by either acute 
aerobic exercise or GC, our results suggest that elevated plasma apelin is associated with 
increased incidence of desensitization to insulin and that lower levels may be related to 
an enhancement in insulin sensitivity.
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CHAPTER I 
INTRODUCTION 
 
 
Novel treatments for diabetes mellitus – particularly type II diabetes mellitus 
(T2D) – are readily studied, as the continual rise in T2D diagnoses elevate global 
healthcare costs.  Total and direct healthcare costs related to diabetes mellitus in 2007 
reached $174 and $118 million, respectively.  To combat this debilitating disease, a 
variety of potential targets have been investigated over recent decades, leading to 
treatments focused on elevating plasma insulin levels, enhancing tissue insulin sensitivity 
and reducing carbohydrate absorption rates, among other interventions (Verspohl, 2012).  
The hallmark of diabetes is insulin resistance, resulting in chronically elevated levels of 
blood glucose, control of which is the ultimate goal of therapy (Cavallo et al., 2012; 
Ringström et al., 2010).  Nearly 1000 therapies have been described, the majority of 
which fail to begin clinical testing, as they neglect the pathophysiological foundations of 
this multifaceted disease.  Potential targets must be mined to reverse the worldwide 
economic burden of T2D and its associated complications.  Continual assessment of the 
molecular players involved in appropriate glucose control is the vehicle by which 
research in this area may progress. 
A molecular target of recent interest is apelin, an adipokine with myriad 
physiological effects and secreted from a variety of tissues, including the heart, 
vasculature, brain and adipose tissue (Kleinz & Davenport, 2005).  Chief among its
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effects is apelin’s purported function in glucose homeostasis and enhancement of insulin 
sensitivity (Dray et al., 2008; Yue et al., 2010).  Recent research suggests that apelin is an 
inextricable component of insulin sensitivity, as reported in studies in apelin knockout 
(APKO) mice compared to wild type controls (Li, Ding, Hassan, Abdelkader, & Shang, 
2013; Yue et al., 2010).  Likewise, acute exercise is reported to confer peripheral and 
hepatic insulin-sensitizing effects, while simultaneously stimulating skeletal muscle 
glucose uptake via insulin-independent translocation of GLUT4 proteins (Devlin, 
Hirshman, Horton, & Horton, 1987; Henriksen, 2002).  An important distinction is to be 
made, as contractile activity increases GLUT4 translocation and subsequent skeletal 
muscle glucose uptake through signaling mechanisms dissimilar from that of insulin 
signaling; however, it is proposed that these paths converge on some downstream 
molecule (Treebak et al., 2014; Vendelbo et al., 2014).  Enhanced contraction-induced 
glucose uptake lasts for up to two hours post-exercise, though the duration of improved 
insulin sensitivity is much longer (Borghouts & Keizer, 2000). 
The mechanism(s) of enhanced peripheral insulin sensitivity following acute 
exercise remains incompletely understood, though it is well known that these benefits are 
transient (Fontana, Klein, & Holloszy, 2010).  Studies vary widely on the topic of time to 
insulin sensitivity reversal following the most recent bout of exercise, providing a range 
of estimates (Borghouts & Keizer, 2000; Heath et al., 1983; Kirwan, Bourey, & Kohrt, 
1991; Magkos, Mohammed, & Mittendorfer, 2010).  Generally it is accepted that these 
benefits are lost within 12-48 hours after the most recent exercise bout (Magkos, 
Tsekouras, Kavouras, Mittendorfer, & Sidossis, 2008).  Exercise training naturally offers 
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an improvement in insulin sensitivity, though trained individuals experience a reversal of 
insulin sensitivity similar to untrained individuals following periods of inactivity (Heath 
et al., 1983; LeBlanc, Nadeau, Richard, & Tremblay, 1981; Ren et al., 1994).  Research 
now suggests that insulin sensitivity enhancement is a benefit facilitated primarily by 
acute alterations to metabolism mediated by single exercise bouts – not exercise training.  
Whereas exercise training has important implications for both healthy and non-healthy 
(i.e. obese, T2D) populations in terms of chronic metabolic control – such as enhanced 
lipid metabolism or increased muscle mass, among other benefits – acute exercise is the 
principal means by which glucose homeostasis is regulated, in terms of the contribution 
to this phenomenon by physical activity (Goodyear & Kahn, 1998; Heath et al., 1983; 
Holloszy, 2005). 
Congruent with our limited understanding of acute exercise’s enhancement of 
insulin sensitivity, apelin’s role in this regard has not been firmly established.  Focused 
study of apelin may provide the insight needed to elucidate our incomplete understanding 
of the mechanisms by which exercise enhances the action of insulin and facilitates blood 
glucose control.  Apelin is reported to enhance peripheral glucose uptake in both normal 
and insulin-resistant rodent models, as shown by intravenous-injected apelin-induced 
blood glucose reductions (Dray et al., 2008).  This study also reported that glucose uptake 
in skeletal muscle was enhanced following apelin injection during a hyperinsulinemic-
euglycemic clamp, demonstrating apelin-induced enhancement of glucose uptake under 
conditions of high blood insulin and normal blood glucose.  Apelin-stimulated glucose 
uptake was confirmed in isolated adipocytes obtained from healthy individuals (Attané et 
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al., 2011; Than et al., 2014) and T2Ds (Dray et al., 2010).  These results collectively 
support apelin’s role as an exogenous insulin sensitizer under conditions of high blood 
insulin.  Whether apelin exhibits similar insulin sensitizing effects under periods of low 
to normal blood insulin in humans is yet to be determined.  In addition, the role of apelin 
as an endogenous insulin sensitizer and blood glucose regulator in normal, healthy 
individuals must be defined. 
Several studies have utilized exercise-training models in attempting to define 
apelin’s proposed insulin sensitizing effects.  There is much dispute across these studies, 
however, and their limitations are multifactorial.  These limitations, detailed herein, have 
resulted in equivocal findings.  The primary issue regarding exercise training-related 
apelin studies is their use of non-healthy subjects; the majority of literature involves the 
response of apelin to exercise training of varied duration in obese and T2D subjects only.  
Obese and T2D populations exhibit considerable variability in apelin concentration, an 
occurrence that is to be expected given the vast number of metabolic contributors known 
to affect blood apelin (Castan-Laurell, Dray, Knauf, Kunduzova, & Valet, 2012; Dray et 
al., 2010; Weir et al., 2009).  Additionally, these studies neglect to report the amount of 
time in the interim between the final exercise bout and post-training blood collection, a 
consideration that must not be ignored when interested in evaluating endocrine and/or 
cytokine response. 
A limitation present in all studies regarding apelin is an indefinite baseline 
concentration in humans.  Reported mean plasma apelin concentration in humans varies 
considerably across literature, from 0.0018–1.25 ng/ml in healthy control subjects, with a 
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collective reported standard deviation of 0.140 ng/ml (Alexiadou et al., 2012; Castan-
Laurell et al., 2008; Cavallo et al., 2012; Dray et al., 2010; Krist et al., 2013; Weir et al., 
2009).  This variability in healthy subjects, not to mention the significant variance in non-
healthy populations, clearly highlights the need for establishing appropriate baseline data 
so that acute and chronic responses of apelin may be appropriately assessed. 
Acute exercise represents an excellent standard by which apelin’s relationship 
with glucose control and insulin sensitivity may be evaluated, given our rich 
understanding of the blood glucose and insulin responses to acute aerobic exercise.  
These responses vary as a function of aerobic intensity and are readily reproducible.  
High intensity aerobic exercise, such as that exhibited during a VO2max test, elevates 
blood glucose and modestly inhibits insulin secretion.  In contrast, moderate intensity, 
steady state aerobic exercise decreases blood insulin while maintaining blood glucose 
(Marliss & Vranic, 2002).  Immediately following bouts of aerobic exercise at high 
intensity (>88% VO2max) there is a spike of blood insulin.  Following both moderate and 
high intensities of acute aerobic exercise insulin sensitivity is transiently enhanced.  This 
phenomenon may be at least partially attributable to apelin’s purported role as an 
endogenous insulin sensitizer.  Apelin synthesis and release is affected by a multitude of 
factors and care must be taken in considering its role across and within specific 
populations.  Thorough evaluation must occur even in apparently healthy individuals, as 
apelin is tightly regulated by blood insulin, hypoxic conditions and adiposity, all of which 
acutely influence glucose flux.  Insulin is considered the greatest regulator of apelin’s 
plasma concentration, a potent signal stimulating apelin’s synthesis and release from 
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adipose tissue, amongst other tissues (Bastard & Feve, 2013; Boucher et al., 2005; 
Sakurai et al., 2013; Than et al., 2014).  In return, it has been shown that apelin exerts 
considerable influence on insulin, acting via APJ receptors located on pancreatic islet 
cells (Ringström et al., 2010; Sörhede Winzell, Magnusson, & Ahrén, 2005).  This 
dynamic interplay represents the crux of this study and no doubt becomes quite complex 
during and following exercise. 
Purpose 
 The primary purpose of this study was to assess the response of plasma apelin to 
two bouts of varied intensity of acute aerobic exercise, as well as to a 54g glucose 
challenge (GC), and to examine the relationship of apelin over time with observed 
alterations in glucose homeostasis and insulin sensitivity. 
Objectives and Hypotheses 
Although regular exercise is justifiably recommended for T2Ds, obese and other 
non-healthy populations in order to mitigate metabolic dysfunction, the mechanisms by 
which acute exercise improves insulin sensitivity and glucose homeostasis needs to be 
more clearly defined.  Apelin’s contribution to these metabolic alterations must also be 
appropriately assessed.  In order to do so, appropriate baseline apelin data must be 
established in healthy populations before characterizing the response of apelin to acute 
and chronic exercise in clinical populations.  In manipulating blood glucose and insulin 
via two acute aerobic exercise conditions and a positive control 54g GC, and by 
performing select assays at four time points (pre-, immediately post-, one hour post- and 
24 hours post-condition), we achieved the following threefold objectives: 
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1. Determined the biological response of plasma apelin to two distinct acute aerobic 
exercise conditions and a 54g glucose load while defining baseline plasma apelin 
concentration. 
2. Evaluated plasma apelin’s relationship with insulin sensitivity, via a validated 
measure of the inverse of sensitivity – insulin resistance, per HOMA-IR – under 
these three conditions. 
3. Assessed the contribution of plasma apelin in the reduction of insulin resistance 
following acute aerobic exercise. 
Following acute aerobic exercise of high-intensity (VO2max), it was hypothesized 
that plasma apelin concentration would be significantly increased from baseline 
immediately post- and 60 minutes post-exercise, resulting from significant increases in 
blood insulin following high-intensity exercise.  In contrast, it was hypothesized that 
acute aerobic exercise of sustained (30 minute) moderate (~70-75% VO2max) intensity 
would not significantly increase apelin concentration immediately post-exercise or 60 
minutes post-exercise, as blood insulin is not shown to increase significantly during these 
periods.  It was also hypothesized that the 54g GC would elicit significant increases in 
apelin concentration immediately post- and 60 minutes post-challenge, resulting also 
from significant increases in blood insulin and blood glucose. 
In addition, it was hypothesized that neither exercise condition would elicit 
significant differences in apelin 24 hours post-exercise from baseline, consistent with the 
transient improvement and subsequent reversal of insulin sensitivity following acute 
bouts of exercise.  It was, however, hypothesized that insulin resistance, as measured by 
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the HOMA-IR index, would be mitigated 60 minutes post-exercise in both conditions, 
with sensitivity improvements reversing thereafter and not significantly different from 
baseline at 24 hours post-exercise; it was hypothesized that insulin sensitivity would not 
be affected by GC one hour and 24 hours post-challenge.  The observed responses of 
plasma apelin and insulin resistance to two varied acute bouts of exercise and 54g GC 
allowed us to assess the endogenous activity of apelin as a circulating insulin sensitizer 
and contributor to whole body glucose homeostasis. 
Assumptions and Limitations 
1. It was assumed that acute maximal, graded aerobic exercise (VO2max) and 
submaximal exercise would elicit well-defined alterations in blood glucose, blood 
insulin, catecholamines, growth hormone and glucagon. 
2. It was assumed that no gender differences existed regarding baseline apelin levels, 
apelin responses to acute exercise or apelin’s influence on glucose homeostasis 
and/or insulin sensitivity. 
3. Blood was drawn solely from an antecubital arm vein and may not have reflected 
whole body or cell-level apelin response, activity or influence on glucose 
homeostasis. 
4. Results may not be wholly generalizable, as they are representative of young, 
healthy human subjects, aged 18-35. 
Delimitations 
1. Apparently healthy subjects, aged 18-35, were recruited to limit between-subject 
variability. 
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2. Subjects were required to keep dietary records prior to each session to assess and 
control for dietary influences on findings. 
3. Subjects were required to discontinue supplementation (>2 weeks) that may 
influence markers of oxidative stress or alter glucose metabolism. 
4. Subjects could not currently be on any medications that might influence 
catecholamines and/or glucose, insulin or fat metabolism. 
Dependent Variables 
1. Plasma Apelin Concentration: ng/ml 
2. Blood Glucose Concentration: mg/dl 
3. Plasma Insulin Concentration: mIU/L 
4. Insulin Resistance: per HOMA-IR index score computation (see Methods) 
5. Resting and Exercise Variables 
a. Heart Rate (HR): in bpm 
b. Oxygen Consumption (VO2) and Maximal Oxygen Consumption 
(VO2max): in L O2/min and ml O2 ⋅ kg-1 ⋅ min-1 
c. Plasma Volume, as hematocrit (%) 
d. Blood Pressure and Mean Arterial Pressure (MAP): in mmHg 
e. Total Work Completed: in Watts (W) 
f. VO2max Test Duration: in mins 
6. Other Descriptive Variables – Resting Values 
a. Body Fat Percentage (BF%) – Siri and Brozek computations 
b. Body Mass Index (BMI): kg/m2 
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Definition of Terms 
1. Adipokine: A cytokine, or cell signaling molecule, released predominantly from 
adipose tissue 
2. Apelin: A classic adipokine, first discovered in 1998 by Tatemoto et al., and the 
endogenous ligand of its receptor, APJ 
3. G Protein-Coupled Receptor (GPCR): A cell surface receptor that initiates 
intracellular signaling via G protein-coupled second messaging 
4. Glucose Challenge: An oral bolus consumption of glucose of a given volume 
5. Glucose Transporter, Type 1 (GLUT1): The predominant glucose transporter 
isoform found in erythrocytes and endothelium of blood-brain barrier 
6. Glucose Transporter, Type 4 (GLUT4): The predominant glucose transporter 
isoform found in skeletal and cardiac muscle and adipose tissue 
7. Homeostatic Model of Assessment of Insulin Resistance (HOMA-IR): An indirect 
method of quantifying insulin resistance and β-cell function, developed in 1985 
by Matthews et al. and correlating strongly with glucose clamp methodology 
8. Insulin Sensitivity: The inverse of insulin resistance, signifies the degree to which 
a cell or tissue responds to the physiological action of insulin 
9. Maximal Aerobic Capacity (VO2max): Or maximal oxygen consumption, refers 
to the maximal volume of oxygen consumption and utilization, typically 
expressed as a volume of oxygen consumed per body weight over a given time 
10. Pyr1-apelin-13: The most biologically potent isoform of apelin, following post-
translational modification of pyroglutamation.
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CHAPTER II 
REVIEW OF LITERATURE 
 
General Apelin Information 
 
Apelin 
 
Apelin, a cytokine primarily synthesized in and secreted by adipose tissue, is the 
endogenous ligand of the G protein-coupled receptor (GPCR) APJ (Tatemoto et al., 
1998).  The family of apelin peptides is derived from a 77-amino acid preproprotein 
(preproapelin) encoded by a single gene, APLN, which, after transcription and 
translation, produces the 8.5 kDa preproapelin.  Angiotensin-converting enzyme 2 
(ACE2) was reported to enzymatically cleave both apelin-36 and apelin-13 peptides, 
though the enzymatic mechanism by which preproapelin is cleaved to its proprotein and 
subsequent other isoforms is unknown (Kalea & Batlle, 2010; Vickers et al., 2002).  
Various isoforms of apelin are biologically active, the most potent and structurally stable 
of which is pyroglutamated apelin-13 (Pyr1-apelin-13) (Kleinz & Davenport, 2005; Zhen, 
Higgs, & Gutierrez, 2013).  Moreover, it has been demonstrated that, as with many 
peptides, the post-translational addition of pyroglutamate to the N-terminus of apelin-13 
(i.e. Pyr1-apelin-13) prevents enzymatic degradation while enhancing biological potency 
(Kleinz & Davenport, 2005).  All identified bioactive isoforms in humans (apelin-12, -13, 
Pyr1-apelin-13, -17, and -36) are known to activate the APJ receptor, ostensibly a 
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requisite for biological activity (Dennis K Lee, George, & O’Dowd, 2006; Zhen et al., 
2013).  The predominant isoforms in humans are apelin-36, apelin-13 and Pyr1-apelin-13 
(O’Carroll, Lolait, Harris, & Pope, 2013) and it has been posited that the length of the 
apelin isoform defines its tissue-specific function, though no studies comparing the 
disparity of isoforms’ efficacies have been carried out (Kleinz, Skepper, & Davenport, 
2005).  The C-terminus region of the apelin peptides seems to dictate its biological 
function, as it has been shown that N-terminal deletions do not appreciably diminish 
function (O’Carroll et al., 2013).  From this point we will collectively refer to the family 
of bioactive isoforms simply as apelin.  The results and discussion sections refer to the 
aggregate of these isoforms, as the methodology used to measure apelin is not sensitive 
enough to distinguish the various isoforms.  Future HPLC assays may help define the 
relative contribution of the various isoforms to their observed function at the tissue level. 
Apelin and APJ exhibit remarkable distribution amongst tissues, with significant 
APJ expression in the thalamus, hypothalamus, frontal cortex and lower brain stem.  
Endothelial and vascular smooth muscle cells (VSMCs) and other peripheral tissues such 
as cardiac myocytes, pancreatic islet cells, skeletal muscle and adipose tissue also exhibit 
considerable APJ concentration.  Substantial APJ and apelin mRNA was reported in 
humans in the spleen and placenta, with considerable apelin content noted in human 
placental tissue (Kleinz & Davenport, 2005; Medhurst et al., 2003).  It is increasingly 
evident that apelin is necessary for cardiovascular development and that this is highly 
conserved across all species.  Apelin functions in various other roles, exerting endocrine 
activity as a circulating peptide, as well as paracrine and autocrine activity, seemingly 
	  13	  
requisite for embryonic and tumor angiogenesis (Kälin et al., 2007; Kleinz & Davenport, 
2005; Ronti, Lupattelli, & Mannarino, 2006). 
APJ 
Apelin exerts its action via binding to APJ, a 380-amino acid GPCR which 
functions putatively through a variety of G proteins to effect downstream signaling 
(Habata et al., 1999; Masri, Lahlou, Mazarguil, Knibiehler, & Audigier, 2002; O’Carroll 
et al., 2013).  Interestingly, it was noted that continued agonist binding of APJ elicits 
receptor internalization and/or altered downstream phosphorylation, leading to 
desensitization and impaired target cell responsiveness (Reaux, Gallatz, Palkovits, & 
Llorens-Cortes, 2002).  Another study showed that duration of receptor internalization 
was correlated with both ligand concentration and isoform type, with longer isoforms 
resulting in longer durations of receptor internalization (Zhou et al., 2003).  Recently, 
Chun et al. (2008) reported that APJ may heterodimerize with other GPCRs, such as 
angiotensin-II type 1 (AT1) in atherosclerotic mouse models, to act constitutively – 
independent of apelin binding.  Li et al. (2012) corroborated these findings, providing 
evidence of APJ heterodimerization with the kappa opioid receptor (KOR).  In the 
presence of either apelin-13 or the endogenous KOR ligand, dynorphin A, in cells stably 
transfected with both receptors, greater extracellular signal-regulated kinase 1/2 (ERK 
1/2) phosphorylation was observed compared with cells transfected with either receptor 
alone.  The variety with which APJ is distributed in concert with its ever-expanding list 
of biological activity implies great tissue- and cell-type-specific functionality. 
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APJ shares remarkable amino acid homology with AT1 (31% total sequence 
homology; 84% transmembrane residue homology), leading to its initially being termed 
AT1-like receptor; yet, angiotensin is not an endogenous ligand of APJ (Ishida et al., 
2004).  GPCRs are abundantly expressed in the cardiovascular system, including 
VSMCs, and APJ is no exception, indicating apelinergic (APJ-apelin) importance in 
regulating blood pressure, angiogenesis and inotropy (Cox, D’Agostino, Miller, Heimark, 
& Krieg, 2006; Kasai et al., 2004; Newson, Pope, Roberts, Lolait, & O’Carroll, 2012).  
Studies of APJ knockout (KO) mice compared with wild-type controls have confirmed 
APJ-apelin influence on cardiovascular homeostasis – both from its action at the 
peripheral tissues and in the forebrain and brainstem – as well as helped define its role in 
regulating hypothalamic-pituitary-adrenal (HPA) activity and the stress response and 
fluid homeostasis.  This perhaps explains the great homology of APJ with AT1 and their 
complementary functionality of fluid and blood pressure regulation (Chandrasekaran, 
Dar, & McDonagh, 2008; Ishida et al., 2004). 
APJ-Apelin on Glucose Homeostasis and Insulin Sensitivity 
Recently APJ-apelin has been identified as a contributor of glucose homeostasis 
and insulin sensitivity (Attané et al., 2011; O’Carroll et al., 2013; Schenk, Harber, 
Shrivastava, Burant, & Horowitz, 2009; Yue et al., 2010).  Numerous studies utilizing 
animal models have reported apelin injection-induced glucose uptake (Attane et al., 2012; 
Dray et al., 2008; Zhu et al., 2011), while similar findings have been confirmed in human 
subjects in vitro (Attané et al., 2011; Dray et al., 2010).  Indeed, it has been suggested 
that apelin is a critical mediator of insulin sensitivity, as Yue et al. (2009) demonstrated 
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by administering apelin to apelin knockout (APKO) mice.  This study also examined 
indices of insulin sensitivity in APKO and wild-type mice and found that APKO mice 
had significantly impaired glucose regulation and insulin resistance.  Another study (Zhu 
et al., 2011) observed apelin-stimulated glucose uptake following TNF-α-induced 
reductions in glucose uptake in 3T3-L1 mice adipocytes, further highlighting the 
significance of apelin’s mitigation of insulin resistance. 
Currently it is incompletely understood how apelin binding to APJ regulates 
blood glucose and purportedly enhances insulin sensitivity.  Specifically, this problem 
relates to whether meaningful apelin action that may lead to enhanced glucose regulation 
occurs centrally or peripherally (i.e. APJ activity at the hypothalamus or via signal 
transduction alteration in insulin-sensitive tissues, such as adipose tissue or skeletal 
muscle), or in concert (Schwartz et al., 2013).  It is well known that alterations of 
hypothalamic neuronal activity may result in altered peripheral glucose metabolism 
(Castan-Laurell et al., 2012).  Nevertheless, the preponderance of research to this point 
has shown that the majority of glucose uptake is mediated by apelin action at skeletal 
muscle, utilizing in vitro animal models and isolated human adipocytes (Boucher et al., 
2005; Castan-Laurell et al., 2012; Dray et al., 2008).  Still, the determination as to 
whether APJ-apelin mediates glucose homeostasis through insulin-dependent 
mechanisms or independent of insulin (or some combination) has yet to be clarified.  
Purported mechanisms of action on glucose regulation and other known physiological 
effects of APJ-apelin are discussed in greater detail below. 
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Proposed Mechanism(s) of APJ-Apelin Signaling Action and Physiological Function  
 
General Signaling and Function of APJ-Apelin 
 
Apelin does not act independently but through a variety of G proteins coupled to 
APJ, which acutely alter cell signaling cascades and participate in cross-talk (Kleinz et 
al., 2005; Langelaan et al., 2013; Masri et al., 2002).  Fundamentally, however, it seems 
that the bioactive isoforms of apelin are, to an extent, distinctly tied to tissue-specific 
responsiveness.  For example, short apelin isoforms, such as apelin-12 and -13, are linked 
to a greater extent in regulating cardiovascular homeostasis and lowering blood pressure 
in rats than their longer peptide counterparts (Hosoya et al., 2000; Zhen et al., 2013); 
short forms of apelin, particularly Pyr1-apelin-13, also predominate in the rodent 
hypothalamus (O’Carroll et al., 2013; A Reaux et al., 2002).  In essence, although short 
and long isoforms of apelin certainly cross-react to activate APJ and display similar 
functionality, they differ by way of tissue distribution, receptor affinity and potency 
(Kleinz et al., 2005).  Research endeavors have adopted a systems approach to identifying 
both the tissue-specific function of APJ-apelin and its participation in downstream 
signaling pathways. 
 As aforementioned APJ-apelin acts via G protein coupling, the multifaceted 
effects of which are dependent on three factors: tissue-isoform specificity, intact tissue 
function and the type of G protein stimulated (Falcão-Pires, Ladeiras-Lopes, & Leite-
Moreira, 2010; Zhen et al., 2013).  APJ-apelin activation has also been shown to induce 
either immediate cellular effect or delayed transcription-level function (Castan-Laurell et 
al., 2012).  To appreciate the salience of intact tissue function, it is helpful to consider 
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APJ-apelin at the endothelium and smooth muscle cells of the peripheral vasculature.  
Herein, apelin acts in an autocrine and/or paracrine fashion, as it is synthesized locally in 
the endothelium, among other tissues.  In the functional endothelium, APJ-apelin acts 
first by stimulating nitric oxide (NO) production through a phosphoinositide 3-kinase 
(PI3K)/Akt mechanism.  APJ-apelin works subsequently on adjacent VSMCs via APJ-G-
inhibitory (Gi) protein coupling with simultaneous NO diffusion into VSMCs, inhibiting 
adenylate cyclase (AC) activity and cyclic adenosine monophosphate (cAMP) production 
and reducing intracellular Ca2+.  This cascade manifests in relaxed vasomotor tone and 
induction of vasodilation.  When considering a non-functional endothelium, however, 
APJ binds apelin directly at the VSMCs, resulting in vasoconstriction from reduced NO 
synthesis coupled with increased Ca2+ production via a phospholipase C (PLC)/PIP2/PIP3 
mechanism – ostensibly through another G protein (Gq) (Falcão-Pires et al., 2010). 
 APJ-apelin may work through Gi, Gq or G stimulatory (Gs) proteins, though it is 
widely accepted that APJ-apelin acts, with rare exception, predominantly via Gi protein 
coupling (Falcão-Pires et al., 2010; Masri et al., 2002; O’Carroll et al., 2013).  It has been 
previously shown that APJ activation induces ERK1/2 phosphorylation via direct 
stimulation of Raf by a DAG/PKC mechanism, independent of Ras (Masri et al., 2002).  
The signaling mechanisms, downstream effector molecules and associated physiological 
effects are highlighted in a system-by-system fashion in the following paragraphs. 
APJ-Apelin and Cardiovascular Physiology 
APJ-apelin plays a critical role in cardiovascular physiology, in terms of 
development, improved cardiac performance and mitigation of dysfunction.  Indeed, 
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apelin’s relation with cardiovascular physiology is the most widely studied.  In 2006, Cox 
et al. reported apelin-dependent vascular development in frog embryos, with apelin 
exhibiting considerable angiogenic activity and induction of endothelial cell proliferation; 
strikingly, this stimulation proceeded in a VEGF-independent manner.  Apelin was found 
to be a potent chemotactic agent in inducing endothelial cell migration.  These findings 
have been corroborated across species in multiple subsequent studies (Cox et al., 2006; 
Kälin et al., 2007; Karpinich & Caron, 2014).  Kasai et al., in 2004, also presented 
evidence of apelin-induced capillary tubule formation in vitro in human RF/6A retinal 
endothelial cells, with neovascularization stimulated equally by Pyr1-apelin-13 and 
apelin-36 in a dose-dependent manner and independent of vascular trophic factors such as 
VEGF and HGF.  In addition it has been established that APJ KO mice suffer lethal 
consequences in utero due to cardiovascular development defects, such as 
underdeveloped hearts and poorly established embryo vasculature. 
Investigators have identified APJ-apelin downstream signaling involvement 
originating from Gα13 protein activation of myocyte enhancer factor 2 (MEF2), a 
transcription factor requisite for embryonic development (Kang et al., 2013).  From the 
perspective of apelin’s importance in angiogenesis, it has also been reported that apelin-
deficient mice exhibit decreased eNOS and lower NO production resulting from 
reductions in Krüppel-like factor 2 (KLF2), a protein of the zinc finger transcription 
factor family necessary for vascular and pulmonary endothelial development and 
upregulated by MEF2 and laminar shear stress (Kang et al., 2013; Takeda et al., 2012).  
The introduction of exogenous apelin has been shown to abrogate these deleterious 
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effects via targeting of AMPK, up-regulating both eNOS and KLF2 (Dray et al., 2008; 
Young et al., 2009).  APJ-apelin initiates a twofold signaling cascade: 1) activation of 
shear stress-responsive channels, which activate MAPK/ERK and MEF2, and 2) 
activation of PI3K, increasing the stability of KLF2 mRNA and the proliferation of 
VSMCs (Young et al., 2009). 
Apelin has also been identified as a potent cardiac inotrope, mediated through 
APJ-apelin activation of PLC, PKC and the Na+/H+ and Na /Ca2+ exchangers (NHE and 
NCX, respectively) (Földes et al., 2003; Szokodi et al., 2002).  Ultimately, activity of 
these mediating proteins increases intracellular Ca2+ levels.  It has been suggested that 
apelin may be an endogenous Ca2+ sensitizer (Chandrasekaran et al., 2008), though it is 
more likely that this positive inotropic function is related wholly to increased calcium 
levels (Falcão-Pires et al., 2010).  Normal and pathological in vivo models have 
consistently shown that the introduction of apelin increases myocardial contractility and 
that APJ presence is obligatory.  In two other studies, it was noted that exogenous 
delivery of apelin did not alter Ca2+ transients, but increased myocardial contractile 
elements’ sensitivity to calcium, indicating potential apelin autocrine activity and 
upregulation during periods of heightened cardiac stress (Charo et al., 2009; Farkasfalvi 
et al., 2007).  Hypoxic conditions initiate the pathways mentioned via hypoxic inducible 
factor alpha-1 (HIF-1α) (Glassford et al., 2007; Ronkainen et al., 2007). 
Apelin’s function as a regulator of vasomotor tone seems to be dependent on 
tissue function, APJ concentration and, as has been posited, the in vivo activity of AT1 
(Jia et al., 2007; Kasai et al., 2004; Liu et al., 2014).  In rodent models, apelin induces 
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acute hypotensive responses in normal and hypertensive animals, and opposes the 
vasopressor activity of the receptor AT1, seeming to suggest that APJ-apelin exerts a 
counter regulatory action to angiotensin II.  To a lesser extent, apelin has been shown to 
be a vasoconstrictor in humans, as well, though often this is a result of pathological 
conditions (Katugampola, Maguire, Matthewson, & Davenport, 2001).  APJ-apelin 
induction of vasodilation is NO-dependent and occurs in stepwise fashion via activation 
of the L-arginine (L-arg)/NOS/NO pathway, potentiating eNOS activity and facilitating 
L-arg transport.  In rat aortic tissue, apelin incubation (10-7 mol/L) increased NO 
production in a dose- and time-dependent manner (Jia et al., 2007).  Despite these effects, 
the literature is controversial with regards to blood pressure, as studies have cited a wide 
range of responses from considerable decreases (Cheng, Cheng, & Pang, 2003; D K Lee 
et al., 2000; Tatemoto et al., 2001) to slight increases in mean arterial blood pressure 
(MABP) in response to apelin treatment in animal models (Katugampola et al., 2001).  It 
is highly likely that apelin-induced vasoconstriction occurs as a response to inactivity of 
angiotensin II vasopressive action or via direct activation of APJ at VSMCs (O’Carroll et 
al., 2013) and predominates in the presence of a functionally intact endothelium. 
Apelin has been identified as a marker of cardioprotection and as a direct 
contributor to lessening the severity of ischemic-reperfusion (IR) injury.  Tao et al. 
(2011) observed that IR injury cardioprotection occurs via a PI3K/p70S6K mechanism, a 
finding confirmed in two other studies (Ronkainen et al., 2007; Zeng et al., 2009).  Some 
dissension has been created on the topic of the mechanism by which apelin induces IR 
cardioprotection.  Another group reported no diminution of Pyr1-apelin-13-induced 
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protection when PI3K and p70S6K inhibitors (wortmannin and rapamycin, respectively) 
were co-administered; no mechanism was posited and this remains a controversial point 
(Kleinz & Baxter, 2008).  Apelin protection in this study occurred only when apelin 
perfusion was initiated just prior to reperfusion/hyperemic period, the period when apelin 
mRNA was drastically upregulated, suggesting that apelin works as an endogenous 
cardioprotective agent upregulated during periods of ischemia.  Human and rodent 
models of heart failure have shown increases in cardiac performance parameters and 
hemodynamics (Ashley et al., 2005; A G Japp et al., 2010). 
APJ-Apelin and Fluid Homeostasis 
APJ-apelin is proven to play a critical role in fluid homeostasis (Kälin et al., 
2007).  APJ and apelin are expressed highly in the paraventricular and supraoptic nuclei 
within the hypothalamus, two of the major sites of hypothalamic regulation of fluid 
homeostasis.  These two sites are major producers of antidiuretic hormone (ADH).  
Apelin acutely alters ADH production in vivo in rodent models; it was observed that 
intracerebroventricular (ICV) injection of apelin-13 and -17 resulted in decreases in 
plasma ADH by 47% and 42.6%, respectively, further suggesting a role for centrally-
acting apelin in the regulation of fluid balance (Reaux et al., 2002; Reaux et al., 2001).  
Ostensibly, apelin exerts similar counter regulatory effects on ADH as it does on 
angiotensin II. 
The effects of apelin injection on rodent water intake have been extensively 
studied, though literature regarding this topic has been equivocal.  Several studies have 
noted greatly reduced or no significant change in water intake upon apelin injection, even 
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in those animals previously deprived of water (De Mota et al., 2004; Reaux et al., 2001; 
Taheri et al., 2002), while others have observed significant increases in water intake (Lee 
et al., 2000).  Both outcomes suggest a critical role for apelin in fluid homeostasis.  
However, it is worth noting that those noting decreases in water intake in rodents 
administered apelin centrally, while the latter chose a peripheral injection route.  The 
dichotomy suggests great importance of APJ-apelin site of activity.  Further study in this 
area is needed to clarify apelin’s role in the regulation of fluid homeostasis. 
Other Physiological Roles 
APJ-apelin is complicit in a variety of other physiological processes, including 
inflammation and immune function (Falcão-Pires et al., 2010; Hosoya et al., 2000; 
O’Carroll et al., 2013), while also exhibiting renal and gastrointestinal function (i.e. 
opposing angiotensin-II response and gastric cell proliferation, respectively) (Hus-
Citharel et al., 2008; Kleinz & Davenport, 2005).  Apelin was also reported to be a potent 
inhibitor of HIV viral entry into CD4+ cells co-expressing APJ (Zhou et al., 2003).  APJ-
apelin undoubtedly plays an important role as a neuroendocrine, as evidenced by its 
central role in fluid homeostasis and plentiful mRNA and protein expression in higher 
centers.  Newson et al. (2013) reported APJ-apelin importance as it relates to HPA-
mediated stress responses, as assessed by CORT (corticosterone) and ACTH change; in 
their study, they noted that apelin modulated the stress response and CORT/ACTH 
release from two imposed stressors: infusion of lipopolysaccharide (LPS) and insulin-
induced hypoglycemia, with only ACTH altered by hypoglycemic condition.  The 
authors herein note that an intact APJ is necessary to induce appropriate ACTH response 
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to these stressors.  This last point, specifically as it relates to APJ-apelin’s compulsory 
role in modulating ACTH, nicely highlights the movement of the literature devoted to 
apelin and its inextricable effects on energy balance.  Recent trends have focused on APJ-
apelin significance to glucose homeostasis and enhancement of insulin sensitivity. 
APJ-Apelin on Energy Metabolism and Glucoregulation 
Apelin is most well known as an adipocyte-derived peptide cytokine (adipokine) 
and has become a recent target of study for its implications in energy metabolism.  Apelin 
is reported to inhibit lipolysis and reduce FFA release through a theorized Gq and Gi 
activation of AMPK (Attané et al., 2011; Yue et al., 2011), and was shown to stimulate 
mitochondrial biogenesis in rodent skeletal muscle through a PGC-1α-directed manner, 
as noted by apelin-induced increases in NRF1 and TFAM (Scarpulla, 2008; Wu et al., 
1999).  These findings have been confirmed in a variety of studies utilizing both animal 
and human models, assessing a variety of mitochondrial markers (Attane et al., 2012; 
Frier, Williams, & Wright, 2009; Yamamoto et al., 2011).  Attane et al. (2012) observed 
apelin-induced increases in fatty acid oxidation, while other groups have noted no 
changes in lipolysis, FFA release or oxidation.  Disparity in the literature may be a 
function of methodology, with some studies utilizing in vivo rodent models and others 
using 3T3-L1 cells to monitor changes in vitro. 
The unclear effect of apelin on lipolysis and lipid oxidation notwithstanding, there 
is clear evidence of apelin’s efficacy as a glucoregulatory factor (Dray et al., 2008).  
Apelin has been demonstrated to induce glucose uptake in humans and animal models in 
vivo and in vitro (Attané et al., 2011; Friedrichsen, Mortensen, Pehmøller, Birk, & 
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Wojtaszewski, 2013; Yue et al., 2010) and this has been proposed to occur through an 
AMPK-dependent mechanism, as AMPK is a well-conserved acute sensor of energy 
regulation and metabolism (O’Neill, 2013); additionally, AMPK is highly activated 
during exercise (Friedrichsen et al., 2013).  It has also been confirmed that apelin-induced 
glucose uptake is NO-dependent in vivo, suggesting an autocrine/paracrine mechanism 
and, perhaps, an irrevocable role for apelin in this mechanism (Duparc et al., 2011).  
Interestingly, apelin also significantly improved glucose uptake and restored insulin 
sensitivity in TNF-α-induced insulin resistant 3T3-L1 cells via a PI3K/Akt, insulin-
mimicking path (Zhu et al., 2011).  In essence, it seems that apelin exerts its 
glucoregulatory effects in an insulin-independent manner, via AMPK, and participates in 
cross-talk in such a way as to induce translocation of glucose transporters, GLUT4 and 
GLUT1, although this has not been confirmed (Higaki, Hirshman, Fujii, & Goodyear, 
2001).  Apelin may function to directly or indirectly alter the insulin signaling pathway 
and further work on this topic is necessary. 
This improved glucose uptake in adipose tissue and skeletal muscle by apelin 
does not reach a magnitude of that induced by insulin (Attané et al., 2011), but may be a 
necessary adjunct to insulin, as it is posited that apelin is necessary to maintain insulin 
sensitivity and beneficial for the reversal of insulin resistance in pathological states.  Yue 
et al. (2010) demonstrated this in APKO mice, which displayed markedly reduced 
adiponectin, significantly diminished insulin sensitivity and hyperinsulinemia; apelin 
injection abrogated these effects, returned insulin sensitivity and induced glucose uptake.  
It is well documented that both apelin and insulin regulate each other, with insulin 
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upregulating apelin and apelin inhibiting insulin secretion at the islet level (Sörhede 
Winzell et al., 2005).  There exists a complex relationship between these key regulators 
of glucose balance and apelin acts as an obligatory metabolic contributor, upregulated in 
periods of energy imbalance and during pathological states, such as T2D and obesity, 
perhaps in a compensatory manner.  A following section, ‘Factors Affecting Blood 
Glucose and Exercise Considerations’, will discuss factors that independently alter blood 
glucose and their relevance to apelin. 
Factors Affecting Apelin Synthesis and Release 
 This section will consider those factors that affect apelin synthesis and release 
with regards to adipose tissue.  A multitude of factors affect apelin’s synthesis and 
circulating levels, the most important regulator of which is blood insulin.  Table 1 lists 
the previously observed resting, post-absorptive apelin concentrations in healthy control 
subjects.  In both in vivo and in vitro studies there is a high correlation between apelin 
and insulin (Boucher et al., 2005).  Hyperinsulinemic mouse models exhibit significantly 
greater apelinemia.  In turn, it has been demonstrated that apelin inhibits insulin secretion 
(Ringström et al., 2010).  Apelin levels are increased in T2Ds and obese individuals, with 
apelin being correlated positively with adiposity, as well.  Having said this, the literature 
is controversial regarding apelin’s relationship with obesity, with many studies showing 
decreased plasma apelin concentration in obese individuals without T2D or with impaired 
glucose tolerance (IGT) (Reinehr, Woelfle, & Roth, 2011).  In general, obesity should not 
be considered the main determinant of apelin increases, but merely contributory (Soriguer 
et al., 2009).  Regional fat distribution and its relation to apelin concentration has not 
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been assessed, nor has visceral or subcutaneous adipose tissues’ relative contribution 
(Blüher, 2014; Habchi et al., 2014), save for one study, which found that viscerally 
located adipose tissue resulted in significantly greater apelin concentration than 
subcutaneous (Krist et al., 2013).  Further exploration into this topic is warranted. 
 
Table 1.  Summary of Apelin Concentration in Healthy Controls.  Only three studies of those known to 
the authors to include healthy controls were omitted from this list, as they either: 1) utilized serum samples 
or 2) did not appropriately control for protease activity and drug action in methodology. 
 
Study Subjects 
Apelin 
Concentration 
(ng/ml) ± SD Procedure Utilized Tissue 
Zhen et al. 
(2013) 
Healthy 
Controls 0.1292 ± 0.02 
Phoenix Pharmaceuticals: 
Apelin-12 HRMB Plasma 
Mesmin et al. 
(2010) 
Healthy 
Controls 0.369 ± 0.08 
Phoenix Pharmaceuticals: 
Apelin-12 HRMB Plasma 
Castan-Laurell 
et al. (2008) 
Healthy Female 
Controls 0.272 ± 0.069 
Phoenix Pharmaceuticals: 
Apelin-12 HRMB Plasma 
Foldes et al. 
(2003) 
Healthy 
Controls 0.0898 ± 0.013 
Phoenix Pharmaceuticals: 
Apelin-36 Human Plasma 
Alexiadou et 
al. (2012) 
Healthy 
Controls 1.25 ± 0.65 
Phoenix Pharmaceuticals: 
Apelin-12 HRMB Plasma 
Papadopoulos 
et al. (2013) 
Healthy 
Controls 0.315 ± 0.147 
Phoenix Pharmaceuticals: 
Apelin-12 HRMB Plasma 
     
 
 
As expected, blockade of the renin-angiotensin-aldosterone system (RAAS) 
upregulated apelin in adipocytes, along with hypoxic conditions and inflammatory 
mediators, namely TNF-α and LPS (Boucher et al., 2005; Dray et al., 2010).  Hypoxia 
has been shown to increase apelin expression in both human and rodent adipocytes in 
vitro (Glassford et al., 2007). Interestingly, PGC-1α is a potent upregulator of apelin in 
adipose tissue in both human and mouse adipocytes (Mazzucotelli et al., 2008). 
 Obviously a plurality of factors induces overexpression of apelin.  Apelin 
expression may be downregulated by several factors, as well, including vitamin C, weight 
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loss and/or hypocaloric diets and a fasted state (García-Díaz, Campión, Milagro, & 
Martínez, 2007).  An interesting factor that acutely downregulates apelin expression is an 
increased concentration of circulating glucocorticoids (i.e. cortisol), though it should be 
noted in the literature that it has been shown only to decrease apelin mRNA (Wei, Hou, 
& Tatemoto, 2005); however, in so doing, it was reported that glucocorticoid-stimulated 
downregulation of apelin gene expression was accompanied by a rise in angiotensin-II.  
This finding has implications in glucose metabolism and obesity-related hypertension 
(among other issues) and, thus, indirect activity on apelin expression (Castan-Laurell et 
al., 2012).  Considering all of this information, the most appropriate assessment of apelin 
regulation would include discussion of insulin, glucose, TNF-α, plasma triglycerides, the 
Homeostasis Assessment Model of Insulin Resistance (HOMA-IR) and HbA1c (Castan-
Laurell et al., 2008; Dray et al., 2010; Heinonen et al., 2009; Soriguer et al., 2009), as it 
has been found that apelin correlates significantly with triglycerides and HbA1c. 
Factors Influencing Blood Glucose and Insulin and Exercise Considerations 
 
Factors Affecting Blood Glucose Concentration 
Blood glucose is regulated in a complex manner and may be altered by a variety 
of inputs, both humoral and neural (Kumar, 1999).  Maintenance of blood glucose within 
a tight physiological range (~80-100 mg/dl fasting; ~80-120 mg/dl at random) is essential 
for whole body glucose homeostasis and is of paramount importance during exercise, 
particularly in diabetics (Vranic, Kawamori, Pek, Kovacevic, & Wrenshall, 1976).  
Traditionally, glucose control has been ascribed to glandular hormone signal integration, 
yet it is evident that the hypothalamus plays a central role and that neural efferents to 
	  28	  
endocrine regulators of blood glucose, namely the pancreas, adrenal cortex and medulla 
and liver, are obligatory (Cherrington, 1999).  APJ and apelin are found in abundance in 
the hypothalamic centers implicated in glucose homeostasis, particularly the 
paraventricular and arcuate nuclei (Knauf, Drougard, Fournel, Duparc, & Valet, 2013; 
McEwen & Reagan, 2004).  As such, it may be that apelin partially mediates central 
glucose homeostasis, as evidenced by centrally-administered apelin-induced glucose 
uptake (Duparc et al., 2011; Knauf et al., 2013).  This section, however, will not expound 
on the purported central role of apelin and will discuss only the hormonal inputs 
regulating glucose homeostasis.  In addition, the key components regulating blood 
glucose during and after acute exercise will be considered. 
 The pancreas and liver play the most critical peripheral roles governing blood 
glucose concentration.  Indeed, the liver exerts tight physiological control on glucose 
production in vivo, responding to efferent signals to stimulate hepatic glucose output 
during periods of low blood glucose (Cherrington, 1999) and during exercise, particularly 
high intensity exercise (Douglas & Rubin, 1963; Marliss & Vranic, 2002).  The pancreas, 
as well responding to neural and humoral efferents, may stimulate either peripheral 
glucose uptake, via insulin, or hepatic glucose production (through glycogenolysis or 
gluconeogenesis), via glucagon; pancreatic α- and β-cells respond quite sensitively to 
blood glucose levels by modifying their secretion of insulin and glucagon with 
remarkable accord.  So sensitive are the α- and β-cells in this process that it has been 
shown in canine models that a decrease in plasma glucose of <0.6 mmol/l results in a 
decrease of insulin output from 78 to 24 pmol/l (Cherrington, 1999).  Somatostatin, also 
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produced by the pancreas (δ cells), suppresses insulin and glucagon secretion, an effect 
predicated on local secretion (i.e. paracrine activity) of somatostatin from the δ cells and 
evidenced via utilization of somatostatin infusion-induced endogenous α- and β-cell 
suppression (Galassetti, Coker, Lacy, Cherrington, & Wasserman, 1999). 
 An array of other hormonal inputs influences the blood glucose response and, 
thus, has profound implications on whole body glucose homeostasis.  Thyroxine 
(Ellenberger et al., 1989; Harrison et al., 1988), β-endorphin (Paolisso et al., 1987; 
Radosevich, Lacy, Brown, Williams, & Abumrad, 1989; Schleicher, Chawla, Coan, 
Martino-Saltzman, & Collins, 1987), growth hormone (GH) (Pritzlaff et al., 2000; Rizza, 
Mandarino, & Gerich, 1982), ACTH and cortisol (Tabata, Ogita, Miyachi, & Shibayama, 
1991; Vila et al., 2010) and the catecholamines, norepinephrine (NE) and epinephrine 
(Epi) (Marliss & Vranic, 2002; Yale, Leiter, & Marliss, 1989), have all been shown to 
influence blood glucose concentration.  Each of these has considerable importance as it 
relates to their secretion during acute exercise bouts, at both moderate and high 
intensities, though the focus of glucoregulation during acute exercise rests decidedly on 
the side of catecholamine-, insulin- and glucagon-driven glucose alterations. 
 Marliss and Vranic (2002) eloquently depicted the various responses of glucose, 
insulin and NE and Epi to two acute bouts of moderate and high intensity aerobic 
exercise, performed, respectively, at 50% and 88% VO2max; these responses are readily 
reproducible at intensities up to ~75% VO2max (moderate intensity) and during VO2max 
testing (high intensity) and have been corroborated by numerous studies (Marliss et al., 
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1992; Marliss et al., 1991; Sigal, Fisher, Halter, Vranic, & Marliss, 1996; Yale et al., 
1989).  Three components of an acute exercise bout – assuming exercise is performed in 
a fasted state – must be observed and comprehended in order to appreciate their discrete 
impacts on blood glucose: 1) the exercise period; 2) immediately acute, post-exercise 
period and; 3) the recovery period.  The responses of the catecholamines, insulin and 
glucagon and their effects on blood glucose at moderate and high intensities of aerobic 
exercise, are discussed accordingly. 
 During acute aerobic exercise of moderate intensity, it has been observed that 
plasma concentrations of NE and Epi do not significantly increase from baseline and that, 
in concert with a slightly increased glucagon-to-insulin ratio (G:I), plasma glucose levels 
are maintained, or perhaps slightly elevated.  Plasma insulin levels are significantly 
depressed during moderate intensity exercise, being inhibited by circulating 
catecholamines and sympathetic (SNS) innervation of pancreatic islet cells (Marliss & 
Vranic, 2002; Suh, Paik, & Jacobs, 2007).  At this intensity of exercise, the insulin 
response is vital, as it sensitizes the liver to glucagon and increases hepatic glucose 
output, which, since it is observed that plasma glucose levels remain relatively constant, 
is tightly matched to glucose uptake.  Thus, at moderate intensity the G:I drives the 
plasma glucose response, as skeletal muscle demand for glucose corresponds nicely with 
hepatic production and output.  Though carbohydrate utilization fuels muscle demand at 
the beginning of moderate intensity exercise, fat oxidation dominates as exercise 
continues, resulting in a decrease in observed RER with less reliance on carbohydrate for 
energy.  Catecholamines play a minor role here and do not increase with any appreciable 
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effect until exercise persists for approximately 1.5 hours or more (Chenevière, Borrani, 
Ebenegger, Gojanovic, & Malatesta, 2009).  Immediately following moderate intensity 
aerobic exercise insulin increases to resting levels or slightly above, in accordance with 
the euglycemic response to moderate intensity, after which time it normalizes to resting 
levels. 
 Intense aerobic exercise (>80% VO2max) provides a stark contrast of substrate 
utilization and glucose response and is driven almost exclusively during exercise by 
catecholamine effects, though it has been shown that GH contributes significantly to the 
glucose response herein (Pritzlaff et al., 2000).  Glucagon may also stimulate hepatic 
glycogenolysis at high intensities, as well (Yale et al., 1989).  During intense aerobic 
exercise there is a demonstrable inequality in glucose output and glucose uptake, such 
that output supersedes uptake and plasma concentration of glucose is elevated – a 
disparity driven by catecholamine-induced muscle glycogenolysis.  Additionally, despite 
elevated glucose concentration, plasma insulin remains depressed below resting levels, 
owing to the glucose-stimulated insulin secretion inhibitory activity (Chiasson, Shikama, 
& Chu, 1981) of the catecholamines, the plasma concentrations of which rise 14- to 18-
fold, or higher (Marliss & Vranic, 2002; Sigal et al., 1996).  Upon cessation of exercise, 
catecholamine concentration drops precipitously, replaced by significant increases in 
plasma insulin that may last for up to 60 minutes post-exercise in humans (Marliss et al., 
1992; Marliss et al., 1991; Sigal et al., 1996). 
 
 
	  32	  
Acute Exercise and Insulin Sensitivity 
At either intensity of aerobic exercise, acute bouts are known to enhance 
peripheral insulin sensitivity, specifically being relegated to the skeletal muscles 
exercised, but with overall improved whole body insulin sensitivity (Bordenave et al., 
2008; Fontana et al., 2010; Heath et al., 1983; Hecksteden, Grütters, & Meyer, 2013; 
Holloszy, 2005).  This is unsurprising given that skeletal muscle, comprising ~45% of 
total human body mass, assumes the vast majority of glucose disposal in response to 
glucose and insulin challenges and following exercise (Henriksen, 2002).  
Simultaneously, through insulin-independent mechanisms, GLUT4 glucose transporters 
are upregulated and translocate to the cell surface during and following muscle 
contractile activity to increase glucose uptake.  This represents an important 
glucoregulatory mechanism in and of itself and is an important adjunct therapy for (and 
efficacious prevention of) T2Ds (Goodyear & Kahn, 1998), though this effect is short-
lived, lasting for ≤2 hours (Borghouts & Keizer, 2000).  In sum, acute bouts of exercise 
improve whole body glucose homeostasis and increase the sensitivity of the periphery, 
namely the liver and skeletal muscle, to insulin for at least 12-16 hours (Borghouts & 
Keizer, 2000; James, Burleigh, Kraegen, & Chisholm, 1983). 
 Aerobic exercise training was found to confer marked enhancement in insulin-
induced glucose uptake in endurance trained individuals compared to controls (Horton, 
1986) and accompanied by lower basal insulin and suppressed insulin response to a 
glucose challenge (GC), despite greater glucose uptake (Galassetti et al., 1999).  Insulin 
sensitivity improvement with exercise training is controversial, however (Hecksteden et 
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al., 2013; James et al., 1983; Segal et al., 1991).  In accord with this finding, it has been 
determined that insulin sensitivity, even in trained individuals, is rapidly reversible 
(Henriksson, 1995) and that acute exercise exhibits primacy with regards to 
improvements in insulin sensitivity (Borghouts & Keizer, 2000; Fontana et al., 2010; 
Heath et al., 1983; Kirwan et al., 1991; Magkos et al., 2010, 2008).  Various suggestions 
have been proposed, yet the precise mechanism by which exercise improves insulin 
sensitivity is not fully understood, and undoubtedly is a multifaceted and multileveled 
lesson in cellular crosstalk. 
Recently, the focus of research regarding insulin sensitivity improvement and 
exercise-induced enhancement of insulin action has focused on AMPK activity, a 
promising prospect regarding insulin sensitivity improvement, as AMPK is a central 
cellular energy homeostasis regulator (Musi & Goodyear, 2006; O’Neill et al., 2013; 
Richter & Hargreaves, 2013).  The consideration of AMPK as a potential player in 
insulin sensitization is warranted, as it is activated by its upstream AMPKK during 
exercise, when myocytes achieve high rates of energy turnover (Friedrichsen et al., 
2013).  Apelin exhibits clear glucose regulation, increasing glucose uptake (Attane et al., 
2012; Attané et al., 2011; Dray et al., 2008; Yue et al., 2010; Zhu et al., 2011) and 
purportedly enhancing insulin sensitivity, ostensibly through an AMPK-dependent 
mechanism (Almabrouk, Ewart, Salt, & Kennedy, 2014; Xu et al., 2012; Yue et al., 
2011).  APJ-apelin’s effects on insulin sensitivity may be mediated via direct 
improvement of glucose uptake and by participation in intracellular crosstalk within the 
insulin signaling cascade or indirect through improvements in energy metabolism, 
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including increased mitochondrial biogenesis (Attane et al., 2012; Frier et al., 2009; 
Röckl, Witczak, & Goodyear, 2008), increased fatty acid oxidation (Attane et al., 2012) 
or participation at the AMPK level (Attané et al., 2011; Yue et al., 2010, 2011). 
At this time, regardless of the mechanism(s) by which apelin exerts its effects, it 
is necessary to more clearly define APJ-apelin’s role on glucose homeostasis and 
maintenance of insulin sensitivity.  Acute aerobic exercise affords an excellent in vivo 
model in which to explore apelin’s relationship with each, as these treatments may 
support or refute the notion that apelin and APJ are necessary for enhancing insulin 
sensitivity. 
Apelin and Chronic Exercise Training 
The literature regarding apelin’s response to aerobic exercise training in humans 
is contentious and limited.  Table 2 lists these studies’ details and outcomes.  Not only are 
these studies few in number, each exhibits multiple limitations that bring into question 
the veracity of their findings with regards to apelin and its role as a glucoregulatory 
factor.  These studies exhibit the following three major limitations: 1) baseline blood 
apelin data is not currently well defined, in either healthy or non-healthy populations; 2) 
these studies report inconsistent mean resting and post-aerobic training values in non-
healthy populations (i.e. obese, T2Ds); and 3) no aerobic training study states precisely at 
what point following training the final blood draw was taken, thus neglecting a critical 
component to any study assessing circulating factors, particularly those theorized to 
contribute to glucose homeostasis and alter insulin sensitivity.  These blood draws were 
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stated to have been taken during a resting, fasted state only (Besse-Patin et al., 2013; 
Kadoglou et al., 2013; Kadoglou et al., 2012; Krist et al., 2013). 
Aerobic exercise training in T2D resulted in significantly elevated serum apelin in 
concert with a decline in blood glucose and insulin, indicating increased insulin 
sensitivity and a potential role for apelin in this phenomenon (Kadoglou et al., 2012; 
Kadoglou et al., 2013).  Krist et al. (2013) observed, however, that obese subjects with 
either T2D or impaired glucose tolerance (IGT), following 12 weeks of aerobic exercise 
(60 minutes/session, 3 sessions/week), had significantly decreased apelin values; yet 
these post-training values were significantly higher than both pre- and post-training 
values in obese with normal glucose tolerance (NGT), likely due to the markedly elevated 
pre- and post-training fasting plasma insulin levels in IGT and T2D subjects, suggesting a 
strong insulin effect on apelin and APJ mRNA. 
 
Table 2.  Summary of Exercise Training Effects on Apelin Concentration.  - Denotes no specific pre-
treatment apelin concentration provided (i.e. only given in illustration). *Significantly different from pre-
treatment (p<0.05). aStudy randomized groups into aerobic, resistance, aerobic plus resistance, and control 
groups. 
 
Study Subjects 
Exercise 
Training Duration 
Pre-Treatment 
Apelin (ng/ml) 
Post-Treatment Apelin 
(ng/ml) 
Fujie et al. 
(2014) Older M/F Aerobic 8 weeks 2.31 ± 0.20 5.00 ± 0.39* 
Besse-Patin et al. 
(2013) Obese Males Aerobic 8 weeks 0.514 ± 0.076 0.490 ± 0.089 
Krist et al. 
(2013) M/F T2D Aerobic 12 weeks - 
10-20% reduction in all 
groups* 
Kadoglou et al. 
(2013) M/F T2D Varieda 6 months - 
Increased	  in	  aerobic	  
and	  combined	  groups* 
Kadoglou et al. 
(2012) M/F T2D Aerobic 12 weeks 0.209 ± 0.102 0.291± 0.135* 
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Both apelin and APJ mRNA were previously shown to be upregulated in adipose 
tissue and skeletal muscle in NGT, but only in skeletal muscle in IGT subjects (Dray et 
al., 2010).  Besse-Patin et al. (2013), however, observed no change in apelin despite 
enhanced insulin sensitivity after eight weeks of aerobic training; these authors confirmed 
Dray et al.’s (2010) previous findings, observing that apelin and APJ mRNA was 
upregulated in skeletal muscle, but not adipose tissue, and that apelin expression and 
secretion was significantly increased in human primary myotubes.  Increased expression 
resulted from cAMP activity and increased Ca2+, corroborating previous studies (Besse-
Patin et al., 2013; Mazzucotelli et al., 2008; Sörhede Winzell et al., 2005).  It bears 
repeating that these studies suffer from the aforementioned limitations, as well as having 
to contend with and make sense of the milieu of inputs regulating the expression of apelin 
and APJ, namely via insulin concentration flux and adiposity (Dray et al., 2010; 
Heinonen et al., 2009; Sörhede Winzell et al., 2005).  Future training studies on this topic 
are essential, yet acute exercise studies in healthy populations are a prerequisite. 
Apelin and Acute Exercise: A Summary 
 To our knowledge this was the first study to examine the effects of acute exercise 
on plasma apelin, specifically the effects of two bouts of aerobic exercise of varied 
intensity on plasma apelin.  More importantly, this study contributes to the body of 
literature by further defining resting, post-absorptive plasma apelin concentration in 
young (18-35 years), apparently healthy individuals, while describing apelin’s 
contribution to glucose homeostasis and insulin sensitivity alteration following acute 
aerobic exercise.  Though observed to induce glucose uptake and to improve insulin 
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sensitivity in vitro as an exogenously delivered peptide, apelin’s in vivo, endogenous 
contribution has been less well reviewed and is quite contentious, a function of this 
topic’s relative nascence (Tatemoto et al., 1998).  In employing exercise protocols known 
to influence blood glucose and insulin in specific manners, we now better understand and 
can ascribe the relative contribution of circulating apelin’s endocrine effects on insulin 
sensitive tissues, specifically skeletal muscle. 
Apelin is known to be secreted from a variety of tissues, notably adipose tissue 
and, more recently, as a skeletal muscle-derived myokine (Besse-Patin et al., 2013).  
Thus, its endocrine effects are likely accompanied by autocrine, paracrine and juxtacrine 
activity (Charo et al., 2009; Kälin et al., 2007; Ringström et al., 2010).  As a result, 
circulating levels of apelin may not necessarily reflect its in vivo activity.  The well-
documented regulation of apelin and insulin, and their known respective feedback and 
feedforward interplay, also suggests obligatory circulating endocrine activity.  The 
mechanism(s) by which apelin induces glucose uptake, contributes to metabolic 
homeostasis and enhances insulin sensitivity have, to this point, been somewhat 
speculative.  Direct or indirect action on the insulin signaling pathway or via AMPK are 
commonly proposed, with the latter, a powerful energy and metabolic sensor, being 
increasingly studied given its activation in skeletal muscle.  Observing the plasma apelin 
response to well-typified acute aerobic exercise protocols in healthy adults limits 
hormonal and pathological signaling milieu present in obese and T2D subjects, thus 
affording the opportunity to better establish apelin’s relevance as an endogenous insulin 
sensitizer and major glucose homeostatic regulator. 
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CHAPTER III 
 
METHODS 
 
 
Subjects 
 
Subjects were consented according to UNCG IRB standards, after which they 
were pre-screened for participation in the study (See ‘Screening Procedures: 
Inclusion/Exclusion Criteria’; Appendices A and B).  Twelve (n=7 male; n=5 female) 
apparently healthy subjects (22.8 ± 2.9 years), not using any tobacco products or taking 
medications/supplements that may alter metabolism, oxidation status, blood glucose 
and/or insulin, were recruited and utilized for this study.  Three subjects from the original 
cohort were excluded from study due to considerable observed resting hypoglycemia, 
along with severe hypoglycemic responses to GC.  A group of twelve subjects was 
determined to be appropriate to yield a power of 0.80, with an alpha level of 0.05 set.  
Subjects utilized in this study had their fitness and exercise habits thoroughly reviewed, 
which were determined to range from moderate to high level of physical activity.  Young, 
apparently healthy individuals were chosen for two reasons: 1) baseline apelin data, at 
rest and following exercise, has not been firmly established in this cohort, prompting the 
need to recruit healthy subjects in order to best define baseline apelin concentration and 
2) establishing this baseline data and response to exercise may be of great future use in 
assessing the role of apelin in non-healthy subjects who exercise.  No gender differences
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have been reported regarding apelin, so the inclusion of both male and female subjects 
was well justified (Krist et al., 2013). 
Study Design 
A repeated measures, 3 (two exercise conditions [VO2max and 70-75% 
submaximal tests] and one 54g GC) x 4 (4 time points [pre-, immediately post-, 1 hour 
post- and 24 hours post-condition]) design was employed for this study.  After a 
screening session, at which participation in the first condition (either VO2max testing or 
GC) was completed, subjects returned to the lab on five other occasions to attain a 24 
hour post-condition blood draw, as well as to complete the final two conditions and 
accompanying 24 hour post-condition blood draws (See Figure 1 for full detail of study 
design protocols). 
Screening Procedures 
Exclusion Criteria 
 Prior to accepting volunteers as official subjects, a screening of potential medical, 
metabolic, cardiovascular, activity and other criteria was completed per approved 
guidelines (Appendices A and B).  Tobacco users and women who were pregnant were 
excluded.  In addition, those volunteers considered obese (per skin folds, who are >2 
standard deviations above the norm for their individual age category) or who are not 
otherwise apparently healthy were excluded from consideration. Volunteer blood 
pressure and body fat percentage was obtained for inclusion purposes.  Volunteers 
meeting criteria for ≥2 cardiovascular risks per ACSM guidelines (Appendix A) were 
excluded from consideration.  Volunteers on any medicines/supplements known to 
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influence metabolism, oxidative stress, and/or inflammation were also excluded, as these 
factors may have confounded outcome measures (Appendix B).  Only those volunteers 
within the age range who meet all of the inclusion criteria were asked to be included as 
official subjects. 
Screening Session 
Consent and screening occurred during the potential subject’s first visit to the 
UNCG Exercise Physiology Laboratory.  Upon arrival volunteers were provided all study 
information and materials, including all assumed subject responsibilities and risks, and 
allowed to ask questions concerning their involvement in the study.  Volunteer informed 
consent was obtained upon agreeing to participate as subjects in the study. The screening 
session was performed after accepting volunteers into the study as subjects. A Pre-
Participation Health/Fitness Facility Screening Questionnaire (Appendix A), as well as a 
fitness and activity level assessment along with the Adapted Health History 
Questionnaire (Appendix B), were completed at this time; subjects meeting exclusion 
criteria per these screening tools were excluded from participation as subjects in the 
study.  Only upon consenting to participate in the study and meeting the aforementioned 
inclusion criteria did volunteers become active subjects.  Resting heart rate, blood 
pressure, weight and height, along with BMI, body fat percentage, WHR and sagittal 
diameter, were then obtained.  Subjects were provided food logs to record all intake three 
days prior to each visit, as well as during the 24-hour period prior to the fourth blood 
draw in each condition.  A study timeline detailing subject involvement is included below 
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(Figure 1), which outlines the procedures upon accepting volunteers as active subjects to 
be included in the study. 
 
Figure 1.  Study Timeline.  Study design and subject involvement through six visits to the exercise 
physiology laboratory, including consent and pre-screening (visit one) to study completion (visit six). 
 
 	  
	  
 
Exercise and Positive Control Procedures 
Subjects completed two exercise conditions (treadmill running – graded [VO2max] or 
steady state [70-75% VO2max]) and one positive control 54g GC condition between 6-9 
a.m. in a post-absorptive (10-12 hours) state, without prior caffeine or alcohol 
consumption (or otherwise contraindicated substance).  Each of these main condition 
visits was separated by at least three days, but not more than 14 days, so as to avoid prior 
condition effects and to ensure no loss of time-dependent insulin sensitivity, respectively.  
Visit	  1:	  VO2max	  or	  
GC;	  3	  Blood	  Draws	  
(pre-­‐,	  post-­‐,	  60	  min	  
post-­‐condition)	  	  
Wait	  24	  hours	  
Visit	  2:	  24	  hour	  
post	  blood	  draw	   Visit	  3:	  One	  of	  two	  remaining	  
conditions;	  3	  Blood	  
Draws	  
Wait	  24	  hours	  
Visit	  4:	  24	  hour	  post	  
blood	  draw	   Visit	  5:	  One	  of	  remaining	  
visits:	  GC	  or	  submaximal	  
test;	  3	  Blood	  Draws	  
Wait	  ≥3	  days	  
Wait	  ≥3	  days	  
Wait	  24	  hours	  
	  
Visit	  6:	  24	  hour	  
post	  blood	  draw	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Each subject also visited the exercise physiology laboratory for a 24-hour post-condition 
blood draw constituting time point four.  Subjects reported to the exercise physiology 
laboratory having not exercised ≥24 hours prior to testing.  The first exercise session 
consisted of a maximal oxygen consumption graded exercise test (VO2max) on a 
treadmill, while the second was a submaximal 30-minute run (at ~70-75% VO2max), also 
performed on a treadmill.  A 54g GC as a positive control was also performed by each 
subject.  These three conditions were randomized, with the only stipulation being that the 
VO2max test must have been performed (for appropriate designation of 70-75% VO2max 
submaximal protocol measures) prior to the submaximal 30-minute run.  Blood was 
obtained from an antecubital arm vein as follows: 
1. Prior to exercise, after ≥15 minutes of rest in laboratory (post-absorptive). 
2. Immediately post-exercise, within one minute of exercise cessation. 
3. 60 minutes post-exercise (resting). 
4. 24 hours post-exercise, at the same time the following morning (resting, post-
absorptive). 
Each exercise session began with a short 3-5 minute gradual warm-up on the treadmill 
and stretching befitting the comfort of each subject.  Proper hydration was ensured to 
maintain appropriate blood volume (BV), with subjects encouraged to intake water ad 
libitum prior to exercise and up to 1000ml intake during the 60-minute interim period of 
rest until the third blood draw.  Water was not provided during the VO2max test, owing to 
the placement of headgear and mouthpiece for the duration of exercise to capture real-
time gas exchange and respiration for calculation of output variables.  Water was 
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provided at least every two minutes during the 70-75% VO2max submaximal test, or 
when the subject requested water, as respiration and gas exchange was assessed via 
mouthpiece every five minutes for ~30s.  Water was provided ad libitum up to 1000ml 
during GC positive control to maintain BV.  Volume of water intake was closely 
monitored and hematocrit measured following each blood draw.  Heart rate was 
continually monitored throughout exercise and recorded every minute during the 
VO2max test and every 5 minutes during the 70-75% VO2max submaximal test.   Subject 
rating of perceived exertion (RPE) was assessed in a similar time frame for each exercise 
session.  Figure 2 outlines the general procedures around each exercise session. 
 
Figure 2.  Exercise Protocol Outline.  General procedures during exercise protocols to be followed for 
each of the two exercise sessions, VO2max and 70-75% VO2max submaximal tests. Both conditions were 
followed by a 24-hour post-exercise resting and post-absorptive blood draw. 
 
 
 
 
 
 
Blood Handling 
Blood was collected in 7 ml K2/K3 EDTA tubes (lavender topped) (2 per time 
point = 14 ml whole blood per time point) from an antecubital arm vein and immediately 
processed for blood measures.  Blood was placed on ice and immediately transported and 
centrifuged in a Beckman Allegra swinging bucket centrifuge for 10 minutes at 3000 rpm 
15	  min	  pre-­‐
exercise	  blood	  
draw	  
3-­‐5	  min	  
warmup	   VO2max	  
Immediately	  
post-­‐exercise	  
blood	  draw	  
60	  min	  resting,	  
fasted	  blood	  
draw	  
15	  min	  pre-­‐
exercise	  blood	  
draw	  
3-­‐5	  min	  
warmup	   Submax	  Test	  
Immediately	  
post-­‐exercise	  
blood	  draw	  
60	  min	  resting,	  
fasted	  blood	  
draw	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(4°C).  A small sample of whole blood (<1µl) was retained to assess blood glucose 
immediately following each blood draw, in duplicate.  Plasma samples were subsequently 
aliquoted into microtubes and placed in an -80°C freezer.  Assays for plasma apelin and 
plasma insulin were completed with batched samples.  To assess hematocrit, a small 
volume of whole blood (<25µl) was placed into micro-hematocrit capillary tubes, sealed 
and centrifuged (American Scientific micro centrifuge) for 5 minutes at 3000 rpm and the 
volume ratio determined, measured as red blood cells to total blood volume, in duplicate. 
Blood Sampling, Assays and Calculations 
1. Blood Glucose – Determined immediately following blood draw utilizing a 
glucose meter (Bayer Contour).  The meter was calibrated for use in duplicate 
each morning prior to blood sampling and between subjects. 
2. Plasma Insulin: Determined following the ELISA immunoassay (10-1113-01) 
procedures described (Mercodia), absorption read at 450 nm via KC Junior 
microplate reader.  Intra-assay variance was <10%.  Inter-assay variance was 
eliminated in batching samples from the same subject on common plates. 
3. Plasma Apelin: Determined following the ELISA immunoassay (EK-057-15) 
procedures described (Phoenix Pharmaceuticals), measured at 450 nm via KC 
Junior microplate reader.  Intra-assay variance was <10%.  Inter-assay variance 
was eliminated in batching samples from the same subject on common plates. 
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4. HOMA-IR: Homeostatic Model of Assessment-Insulin Resistance (HOMA-IR), 
was measured to assess insulin resistance, the reciprocal of insulin sensitivity, 
using the following calculation: 
 
HOMA-IR = [FPG][FPI] ÷ 405, 
 
 
where FPG is fasting plasma glucose, in mg/dl, and FPI is fasting plasma insulin, 
in mU/L.  In this model, a decrease in HOMA-IR represents an improvement in 
insulin sensitivity.  The HOMA-IR index has been shown to correlate well with 
studies utilizing glucose clamp methodology (Muniyappa, Lee, Chen, & Quon, 
2008). 
Statistical Analyses 
Power Analysis 
The subject n value was judged appropriate for this study (n=12), yielding a 
power >0.80 based on a sample size of n=8 and population mean and standard error of 
0.438±0.017 ng/ml for normal, healthy controls in seven previous studies (Table 1), 
utilizing a two-tailed test with an α=.05. 
Exercise Variables and Total Work Completed 
All exercise variables and total work completed during each exercise condition 
were analyzed via repeated measures analysis of variance (RMANOVA).  Additionally, 
changes in apelin concentration under exercise conditions were assessed as a function of 
total work completed. 
 
	  46	  
Assessing Main and Interaction Effects 
Plasma apelin, blood glucose, plasma insulin, insulin sensitivity and hematocrit 
were analyzed via 3 (two exercise conditions [VO2max and 70-75% submaximal tests] 
and one 54g GC condition) x 4 (4 time points [pre-, immediately post-, 60 minutes post- 
and 24 hours post-condition]) RMANOVA to detect main and interaction effects.  
Bonferroni post hoc tests were employed to identify where main effect significance was 
noted.  RMANOVA was performed separately by condition for simple main effects upon 
achieving a significant interaction effect. 
Plasma Apelin Relationship with Insulin Resistance 
A Pearson product-moment correlational coefficient (PPMC) was used to analyze 
relationships of absolute plasma apelin values with that of blood glucose and plasma 
insulin, as well as with insulin resistance across conditions by time.
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CHAPTER IV 
RESULTS 
 
This chapter presents the results of the current study and is organized into the 
following areas: subject descriptive characteristics, VO2max and submaximal data, 
hematocrit and plasma volume response to each session and, finally, blood marker 
outcomes, including plasma apelin, blood glucose, plasma insulin and insulin resistance, 
as measured by the HOMA-IR index. 
Subjects 
 
 
Table 3.  Subject Baseline Descriptive Characteristics.  Expressed in 
overall terms and by gender.  Values shown are means ± standard deviation. 
*Significantly different between genders (p<0.05). 
 
Variable Overall Males (n=7) Females (n=5) 
Age (yrs) 22.75 ± 2.96 22.43 ± 2.88 23.2 ± 3.35 
Weight (kg) 68.56 ± 13.08 72.14 ± 15.11 63.54 ± 8.59 
Height (cm) 171.04 ± 7.53 174.29 ± 5.82 166.5 ± 7.8 
BMI 23.37 ± 3.55 23.66 ± 3.96 22.96 ± 3.27 
BF% 15.32 ± 8.09 11.02 ± 6.11* 21.33 ± 6.84* 
RHR (bpm) 65 ± 9.17 63.43 ± 9.07 67.2 ± 9.86 
Resting SBP (mmHg) 119.67 ± 9.34 120.29 ± 9.83 118.8 ± 9.65 
Resting DBP (mmHg) 77.83 ± 7.29 76.57 ± 8.04 79.6 ± 6.54 
Resting MAP (mmHg) 91.78 ± 7.29 91.14 ± 8.51 92.67 ± 6.02 
VO2max (L/min) 3.49 ± 0.95 4.02 ± 0.86* 2.77 ± 0.47* 
VO2max (ml/kg/min) 51.14 ± 11.07 56.17 ± 10.32 44.09 ± 8.42 
 
 
Each subject (n=12) reported to the UNCG exercise physiology laboratory at a 
similar time across conditions (between 6-9 a.m.), in a resting, post-absorptive state.
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Each subject successfully completed all treatment conditions, as well as achieving a true 
VO2max (51.14 ± 11.07 ml ⋅ kg-1 ⋅ min-1) during maximal oxygen consumption testing, 
per established criteria (Midgley, McNaughton, Polman, & Marchant, 2007).  In addition, 
each subject visited the lab for his or her 24-hour post-treatment visit at precisely the 
same time as the previous visit, so as to ensure an accurate 24-hour post blood draw and 
resting measures. Each subject participated in a body composition analysis on the first 
visit, which included assessment via seven-site skinfold for % body fat determination, 
sagittal-abdominal diameter, waist circumference and WHR measures.  All baseline and 
resting measures were taken ≥15 minutes prior to exercise and glucose gel consumption.  
Resting measures and blood draws taken during the 24-hour post-treatment visits were 
also taken with ≥15 minutes rest in a post-absorptive state. 
VO2max and Submaximal Test Exercise Outcomes 
 
 
Table 4.  Exercise Variables and Total Work Completed.  Includes VO2max test and 70-75% VO2max 
submaximal run.  Heart rate measured in beats per minute (bpm).  Values shown are mean ± standard error 
of the mean. *Significantly different between genders (p<0.05). †Significantly different between conditions 
(p<0.05). 
 
 
HRmax: 
VO2max 
VO2max 
Duration 
(mins) 
%VO2max: 
Submaximal 
Test 
Mean HR: 
Submaximal 
Test 
Total Work 
VO2max 
(Watts) 
Total Work 
Submaximal 
(Watts) 
 
Overall 
187.2 ± 
1.77 6.89 ± 0.30 72.71 ± 1.01 166.22 ± 3.36 
876.36 ± 
105.54† 
1345.41 ± 
173.58† 
 
Male 
187.86 ± 
2.87 7.16 ± 0.42 73.59 ± 1.43 167.19 ± 4.48 
1064.5 ± 
122.18*† 
1558.32 ± 
164.58† 
 
Female 
186.2 ± 
1.77 6.52 ± 0.42 71.48 ± 1.31 164.87 ± 5.63 
612.97 ± 
111.53* 
1047.33 ± 
322.35 
 
 
Total work completed was computed for each subject for both the VO2max 
test and 70-75% VO2max submaximal test, both of which were completed on a 
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treadmill with real-time HR monitored throughout with a digital HR monitor (Polar).  
Table 4 displays these mean exercise and total work completed data.  In addition, to 
ensure appropriate exercise intensity for the duration of the submaximal test, subject 
HR, RPE (not shown) and %VO2max was monitored and recorded every five 
minutes.  Figure 1 displays the mean %VO2max during the 30-minute submaximal 
run across time.  Total work completed was recorded in both exercise conditions in 
order to account for workload- and/or duration-mediated alterations in plasma 
apelin, blood glucose, plasma insulin and insulin sensitivity improvements. 
 
Figure 3.  30-Minute Submaximal Exercise Intensity.  %VO2max, as relative exercise 
intensity, at five-minute intervals during the 30-minute 70-75% VO2max submaximal 
treadmill test. No significant differences amongst intervals over time were noted. 
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As is evidenced in Figure 3 above, the cohort maintained appropriate intensity – within 
the prescribed 70-75% VO2max range – throughout the entirety of the 30-minute 
submaximal test. 
Plasma Volume and Hematocrit 
 To assess the response of plasma volume to acute aerobic exercise in both 
exercise conditions, as well as during the 54g GC condition, hematocrit was measured at 
each time point.  Table 5 displays these data. 
 
Table 5.  Mean Hematocrit Measures.  Mean values (± SD), as %, across time in each study condition. 
 
Time VO2max Test 70-75% VO2max 54g Glucose Challenge 
Pre (1) 46.33 ± 2.19 46.91 ± 2.23 46.39 ± 1.77 
Post (2) 46.37 ± 1.58 46.40 ± 2.10 47.39 ± 1.55 
1 hr Post (3) 45.49 ± 1.48 46.06 ± 1.95 46.46 ± 1.69 
24 hr Post (4) 45.95 ± 1.25 46.79 ± 1.69 45.72 ± 1.64 
    
 
No significant differences exist between times one and two (pre- and post-treatment) in 
any condition, suggesting appropriate control of plasma volume via hydration during 
exercise and glucose consumption.  Table 6 displays the RMANOVA results, revealing 
no significant interaction or main effects on plasma volume. 
 
Table 6.  RMANOVA Results for Hematocrit Across Condition by Time. 
 
Effect df F-value Significance 
Condition 2 1.087 0.355 
Time 3 2.297 0.097 
Interaction 6 0.982 0.445 
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Males exhibited a significantly higher hematocrit than females in conditions B (p=0.016) 
and C (p=0.029), though there were no differences exhibited by either gender across time. 
Blood and Plasma Outcome Markers 
Plasma Apelin 
 RMANOVA results showed no significant interaction or main effects of exercise 
or GC on plasma apelin (as shown in Table 7).  Figure 4 displays the plasma apelin 
response across each condition over time.  No significant differences were noted in 
plasma apelin by condition or across time.  No mean differences or effects were observed 
for plasma apelin by gender (p=0.616). 
 
Figure 4.  Plasma Apelin Response by Condition.  The plasma apelin (mean ± SE) response across 
each condition over time. VO2max. n70-75% VO2max submaximal run. u54g glucose challenge. 
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Table 7.  RMANOVA Results for Plasma Apelin Across Condition by Time 
 
Effect df F-value Significance 
Condition 2 1.187 0.324 
Time 3 0.579 0.633 
Interaction 6 2.037 0.073 
 
Blood Glucose 
 Blood glucose was also assessed utilizing 3x4 RMANOVA, with these results 
expressed below in Table 8.  A significant condition by time interaction effect, F (2.307, 
25.381)=4.783, p=0.014, was observed. 
 
Table 8.  RMANOVA Results for Blood Glucose Across Condition by Time. 
 
Effect df F-value Significance 
Condition 1.370 6.36 0.016 
Time 3 35.702 <0.001 
Interaction 2.307 4.783 0.014 
 
 
Figure 5 below details the blood glucose response by condition over time.  It should be 
noted that the mean blood glucose response following GC is diluted by three (n=3) 
subjects who seemed to elicit no response to the challenge.  This finding is explained 
below in the Plasma Insulin subsection, as each of these outliers exhibited considerable 
hyperinsulinemia post-challenge.  Omitting these three subjects’ post-challenge blood 
glucose concentration increases the mean (± SE) blood glucose to 116.31 ± 3.3 mg/dl.  A 
Bonferroni post hoc analysis was utilized to assess mean differences over time and by 
condition.  Significant results and comparisons are noted in Figure 5 below.  No 
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significant differences existed between male and female at any time point across 
conditions (p=0.896). 
 
Figure 5.  Blood Glucose Response by Condition.  The blood glucose (mean ± SE) response 
across each condition over time. *Significantly different from all other times in condition (p<0.05). 
†Significantly different from 70-75% VO2max Post (p<0.05). •VO2max. n70-75% VO2max 
submaximal run. u54g glucose challenge. 
 
 
Plasma Insulin 
 
RMANOVA of plasma insulin revealed a significant condition by time interaction 
effect, F (1.405, 15.454)=15.423, p=0.001.  These data are shown in Table 9.  Figure 6 
illustrates the observed plasma insulin response by condition at each time point.  As 
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comparison was performed.  Significant results and comparisons are noted in Figure 6 
below. 
 
Figure 6.  Plasma Insulin Response by Condition.  The plasma insulin (mean ± SE) response 
across each condition over time. *Significantly different from all other times in condition (p<0.05). 
†Significantly different from 70-75% VO2max Post (p<0.05). ‡Significantly different from VO2max 
Post (p<0.05). •VO2max. n70-75% VO2max submaximal run. u54g glucose challenge. 
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GC.  Omitting these three subjects’ post-GC plasma insulin concentration reduces the 
mean (± SE) plasma insulin to 33.98 ± 5.29 mIU/L, which was still significantly elevated 
relative to both exercise conditions.  No significant differences existed between male and 
female at any time point across conditions (p=0.627). 
 
Table 9.  RMANOVA Results for Plasma Insulin Across Condition by Time. 
 
Effect df F-value Significance 
Condition 1.135 24.064 <0.001 
Time 1.333 51.167 <0.001 
Interaction 1.405 15.423 0.001 
 
 
Insulin Resistance: HOMA-IR Index 
 Table 10 displays the 3x4 RMANOVA results comparing HOMA-IR index scores 
across conditions over time, while Figure 7 illustrates these mean HOMA-IR scores by 
condition.  HOMA-IR scores immediately post-treatment (time point two) are not 
necessarily reflective of overall resistance to insulin, as this indirect method requires 
calculation utilizing a constant value and fasting levels of blood glucose and insulin, the 
concentrations of which rise considerably following a GC and highly intensive aerobic 
exercise >80% VO2max (Marliss & Vranic, 2002).  A greater appreciation for insulin 
resistance as it relates to the HOMA-IR index may be gained by assessing ΔHOMA-IR 
scores over time following treatment (where a decrease in HOMA-IR score represents an 
improvement in insulin sensitivity), while considering established diagnostic cutoff 
values based on ethnicity, medical history and risk stratification (Gayoso-Diz et al., 
2013).  No significant effects by gender were observed for HOMA-IR scores (p=0.736). 
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Table 10.  RMANOVA Results for HOMA-IR Scores Across Condition by 
Time. 
 
Effect df F-value Significance 
Condition 1.075 20.197 0.001 
Time 1.291 86.542 <0.001 
Interaction 1.301 16.617 0.001 
 
 
Figure 7.  HOMA-IR Response by Condition.  HOMA-IR index scores (mean ± SE) across each 
condition over time. *Significantly greater than all other times in condition (p<0.05). †Significantly 
greater than 70-75% VO2max Post (p<0.05). ‡Significantly greater than VO2max Post (p<0.05). 
§Significantly lower than Pre and Post measures (p<0.05). 
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Plasma Apelin and its Relation to Insulin Resistance 
 To further examine the purported relationship between blood apelin and insulin 
concentrations, mean resting plasma apelin concentration was correlated with mean 
resting plasma insulin, obtained from pre-treatment resting blood samples across each 
condition.  Figure 8 displays this relationship, which exhibited a significant correlation 
(R=0.702, p=0.011).  Furthermore, there was a significant relationship observed between 
resting plasma apelin concentration and HOMA-IR score (R=0.738, p=0.006).  This 
relationship is illustrated in Figure 9 and expounded on at length in the Discussion 
section. 
To elucidate the importance of plasma apelin as it relates to improvements in 
insulin sensitivity, plasma apelin concentration was correlated with insulin resistance at 
each time point across conditions, specifically concerning the 70-75% VO2max 
submaximal test, as it was the only condition to elicit a statistically significant decrease in 
insulin resistance at one hour compared to pre (p=0.024) and post (p=0.005) measures.  
Following VO2max and GC at 1 hour (VO2max: R=0.392; GC: R=0.332) and 24 hours 
(VO2max: R=0.29; GC: R=0.307), no significant relationship existed between plasma 
apelin and insulin resistance, as measured by HOMA-IR index.  However, by one hour 
post-70-75% VO2max submaximal treadmill test, plasma apelin was significantly 
correlated with HOMA-IR score (R=0.672, p=0.017), though not at 24 hrs, consistent 
with the reversal of insulin ~24 hours post-exercise bout.  These data suggest a negative 
correlation between plasma apelin and insulin sensitivity, whereby elevated 
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concentrations of plasma apelin yield greater insensitivity to insulin in this healthy 
cohort.  These data are displayed in Figure 10. 
 
Figure 8.  Plasma Apelin and Insulin.  The relationship between resting plasma apelin and 
plasma insulin (R=0.702, p=0.011). 
 
 
 
Figure 9.  Plasma Apelin and Insulin Resistance at Rest.  The relationship between plasma 
apelin and insulin resistance, as determined by the HOMA-IR index, at baseline (R=0.738, 
p=0.006). 
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Figure 10.  Plasma Apelin and Insulin Resistance Following Sustained Aerobic Exercise.  
The relationship between plasma apelin and insulin resistance, as determined by the HOMA-IR 
index, following the 70-75% VO2max submaximal treadmill test at one hour (R=0.672, p=0.017). 
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CHAPTER V 
 
DISCUSSION 
 
 
The primary purpose of the current study was to examine the effects of acute 
aerobic exercise on plasma apelin, as a function of aerobic exercise intensity, as well as 
to a 54g GC serving as a positive control, in young, apparently healthy individuals.  This 
study sought also to achieve two secondary aims: to define appropriate resting plasma 
apelin concentration in apparently healthy adults and to assess the relationship of plasma 
apelin to insulin sensitivity. 
Both male and female subjects were included in the current study, as previous 
literature has shown no significant differences in resting or post-training apelin 
concentration between genders (Alexiadou et al., 2012; Krist et al., 2013; Mesmin, 
Dubois, Becher, Fenaille, & Ezan, 2010).  The current study noted no significant 
difference in resting plasma apelin concentration by gender (p=0.141), supporting this 
contention in previous literature.  In fact, resting plasma apelin amongst all twelve 
subjects was quite stable across visits (p=0.990).  No significant differences existed by 
gender in blood glucose or plasma insulin, nor did subjects differ significantly in other 
baseline and resting measures by gender, with the exception of % body fat (11.02 vs. 
21.33% in males and females, respectively). 
Total work performed in the VO2max test, as well as absolute VO2max, were 
significantly different by gender (Tables 1 and 2), though total work completed and total 
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caloric expenditure during exercise did not contribute to any observed differences in our 
blood markers of interest.  A near-significant difference was also observed for relative 
VO2max by gender (p=0.057).  An abundance of literature exists regarding aerobic 
fitness and the potential benefits conferred regarding adipokine makeup though, with 
regards specifically to apelin, data is limited.  Study of the effects of fitness on notable 
adipokines has returned contentious findings.  Some maintain that individuals with 
greater aerobic fitness tend to have favorable adipokine levels (Fontana et al., 2010; 
Tomaszewski et al., 2003), while others note no significant benefits of fitness on 
adipokine profile in the absence of weight reduction (Christiansen, Paulsen, Bruun, 
Pedersen, & Richelsen, 2010; Kelly, Steinberger, Olson, & Dengel, 2007; Kondo, 
Kobayashi, & Murakami, 2006; Ziccardi, 2002).  Subjects utilized in the current study 
demonstrated good or better aerobic fitness, as described by the American College of 
Sports Medicine guidelines for fitness and exercise prescription, as well as average or 
better % body fat.  Thus, our inclusion of apparently healthy, aerobically fit subjects 
limited our ability to fully examine the influence of fitness on plasma apelin 
concentration.  A greater spectrum of aerobic fitness is likely necessary to truly assess 
this phenomenon.  Moving forward, the effects of aerobic fitness on resting plasma apelin 
concentration should be explored. 
 To the authors’ knowledge this is the first study to assess the effects of acute 
aerobic exercise on plasma apelin and, as a corollary, the contribution of apelin in the 
transient improvement of insulin sensitivity following aerobic exercise.  Previous 
exercise-related studies regarding apelin have focused entirely on the effects of training, 
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establishing findings related to exercise chronicity, as opposed to the current study’s 
focus on acute alterations in plasma apelin.  Despite the burgeoning body of literature in 
recent years, results regarding apelin’s response, activity and contribution to insulin 
sensitivity are equivocal (Besse-Patin et al., 2013; Fujie et al., 2014; Kadoglou et al., 
2010, 2012; Krist et al., 2013).  The exclusive selection of obese individuals, T2Ds 
and/or older adults for inclusion in these studies is but one of their multifactorial 
limitations.  It was, therefore, imperative to address the need for appropriate definition of 
resting apelin level, as well as the acute effects of exercise on apelin concentration, in 
apparently healthy young adults. 
To this end, we elected to discern the response of plasma apelin to bouts of 
maximal (VO2max) and submaximal (30-minute 70-75% VO2max) aerobic exercise, as 
compared to a 54g glucose challenge (GC), a stressor known to significantly elevate 
blood glucose and insulin.  The controlled manipulation of glucose and insulin was a key 
element in the current study of apelin.  Highly (>80% VO2max) intensive aerobic 
exercise demonstrates empirically characterized and readily reproducible alterations in 
blood glucose and blood insulin (Marliss & Vranic, 2002), the latter of which is the most 
potent signal for the synthesis and secretion of apelin from adipose tissue.  High-intensity 
aerobic exercise elevates blood glucose during exercise and causes a surge in insulin 
immediately following exercise, while moderate intensity aerobic exercise is a model of 
euglycemia and stable insulinemia both during and following activity.  Furthermore, it 
has been consistently reported that following acute aerobic exercise – particularly after 
sustained, moderate intensity (50-75% VO2max) exercise – insulin sensitivity is 
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enhanced (Bruce & Hawley, 2004; Cartee et al., 1989; Heath et al., 1983; Holloszy, 2005; 
Magkos et al., 2008; O’Neill, 2013).  Whether apelin is implicit in this improvement, 
irrespective of alterations in blood glucose and insulin, is not currently known. 
Understanding these principles, we hypothesized that plasma apelin concentration 
would be significantly increased from baseline immediately post- and one-hour post-
VO2max, resulting from significant increases in plasma insulin following the surge of 
blood glucose during maximal exercise.  It was also hypothesized that the 54g GC would 
elicit significant increases in plasma apelin concentration immediately post- and one hour 
post-challenge, resulting also from significant increases in plasma insulin and blood 
glucose.  In contrast, it was hypothesized that acute aerobic exercise of sustained (30 
minutes) moderate (~70-75% VO2max) intensity would not significantly increase apelin 
concentration immediately post-exercise or one hour post-exercise; blood insulin has not 
been shown to change significantly during or following this stressor, as euglycemia is 
typically maintained at moderate intensities.  In addition to these hypotheses, it was also 
hypothesized that plasma apelin would return to baseline after 24 hours in each condition. 
As our data demonstrate, both exercise protocols and the 54g GC elicited 
anticipated blood glucose and plasma insulin responses.  Blood glucose was significantly 
elevated from baseline following both VO2max (111.25 ± 5.6 mg/dl, p=0.001) and GC 
(104.63 ± 5.9 mg/dl, p=0.002), but not following the submaximal bout (84.83 ± 4.1 
mg/dl).  In addition, plasma insulin was significantly elevated following VO2max (19.59 
± 1.8 mIU/L, p=0.001) and GC (46.64 ± 6.4 mIU/L, p=0.001).  As expected, the 
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submaximal bout did not elicit significant alterations in plasma insulin (13.08 ± 0.9 
mIU/L).  Despite these anticipated spikes in insulin, plasma apelin was not significantly 
altered immediately post- or one hour post-treatment following VO2max; the 54g GC 
elicited a non-significant elevation of plasma apelin one hour post-challenge (p=0.223).  
We therefore reject these hypotheses and accept the nulls.  Conversely, we accept our 
hypothesis concluding that submaximal exercise would not significantly alter plasma 
apelin concentration over time.  We also accept our hypothesis that plasma apelin will 
have resumed baseline, resting concentration at 24 hours post-treatment, as this was 
observed under each condition. 
It is surprising that no significant changes in plasma apelin concentration were 
observed across conditions or over time, despite both VO2max and GC modalities 
effecting the specified elevations in blood glucose and plasma insulin.  Moreover, we 
noted a significant correlation between mean resting plasma apelin and plasma insulin 
(R=0.702, p=0.011), strengthening the foundation of our hypotheses and suggesting that 
elevated insulin would indeed lead to an increase in plasma apelin.  To rationalize these 
findings contrary to our hypotheses, it is useful to revisit the complex interrelationship 
that exists between apelin and insulin, and how secretion signaling and its time course, as 
well as exercise-mediated and postprandial insulin signaling, may have differentially 
influenced our results. 
Firstly, it must be considered that apelin might not be significantly affected 
acutely in vivo, either by exercise or by GC.  Rather, changes in apelin may occur only as 
a result of chronic treatment or conditions.  As no previous literature has examined apelin 
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following acute exercise, no comparisons can be drawn here; the fact that chronic 
exercise studies are ambiguous on this topic further complicates our understanding of 
exercise-related apelin changes.  However, regarding glucose consumption, in humans it 
has been demonstrated that no significant elevation in apelin occurs following OGTT for 
three hours (Alexiadou et al., 2012).  This in vivo evidence substantiates our finding that 
apelin is not acutely affected by GC, provided the challenge in our study (~54g) and the 
aforementioned study (unspecified; likely 75g) was of sufficient dose.  Deficits in the 
current study’s experimental design surely exist herein, as it relates to the proposed effect 
of insulin on apelin.  Apelin has a short circulating half-life, approximately 5-8 minutes, 
and its degradation could chiefly affect our results (Japp et al., 2008; Yu et al., 2013).  
More importantly, difficulties pertaining to apelin’s half-life, in concert with the relative 
uncertainty regarding the time course of insulin-apelin signaling and secretion, limits our 
ability to conclusively interpret apelin changes post-treatment.  The lack of blood 
sampling beyond one hour until 24 hours post-treatment in the current study may have 
precluded observable, significant findings; more frequent sampling to obtain a detailed 
plasma apelin profile may have afforded a more accurate glimpse into apelin’s response 
to exercise and effects on insulin sensitivity, particularly given its short circulating half-
life. 
A few studies have suggested a time course relationship between insulin 
administration and apelin up-regulation in vitro; significant apelin mRNA elevations in 
these studies occur between three and twelve hours post-insulin administration in isolated 
adipocytes, though this may not necessarily reflect local or circulating apelin levels and 
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activity at insulin sensitive tissues in vivo (Boucher et al., 2005; Daviaud et al., 2006; 
Glassford et al., 2007; Wei et al., 2005).  Significant findings may have been observed 
had we sampled blood beyond one hour, per the aforementioned studies’ proposed 
insulin-apelin time course, though these in vitro findings may not reflect in vivo insulin-
apelin synthesis and secretion signaling. 
Apelin is known to exert considerable influence on insulin secretion from 
pancreatic β-cells in vivo and in vitro, inhibiting glucose-stimulated insulin release (Guo 
et al., 2009; Ringström et al., 2010; Sörhede Winzell et al., 2005).  Consequently, full 
consideration of the dynamic relationship between apelin and insulin must be given.  The 
present study, in examining alterations only up until one hour post-exercise in the 
immediately acute period, may have missed apelin alterations between this time point and 
24 hours.  How this relationship develops and is altered over time should be explored by 
future studies following both acute and chronic exercise. 
Beyond these considerations, it should also be noted that apelin, as an adipokine 
and ubiquitously released cytokine, has been shown to partake in activity outside of its 
contribution as a circulating endocrine molecule.  It has been well documented that apelin 
exerts paracrine and autocrine activity (Kälin et al., 2007; Kleinz & Davenport, 2005; 
Ronti et al., 2006) and that apelin-mediated glucose uptake in vivo is a NO-dependent, 
autocrine/paracrine process (Duparc et al., 2011).  It also remains unclear what effect 
other cytokines exert on cellular release of apelin, and how these effects may vary by 
tissue.  Little research exists on this topic, though it was established that TNF-α up-
regulates apelin mRNA and plasma levels (Daviaud et al., 2006).  This finding may 
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suggest a link between the inflammatory state common in obesity and T2D and a 
potential protective mechanism, whereby up-regulated apelin contributes to improved 
insulin responsiveness.  This notion is strengthened further by evidence of apelin up-
regulation following induction of PGC-1α (Mazzucotelli et al., 2008), which has been 
shown to improve lipid utilization and glucose disposal in both skeletal muscle and white 
adipose tissue obtained from lean and obese T2D subjects (Benton et al., 2010).  In short, 
exercise-induced cytokine and gene effects on apelin should be explored, as apelin’s 
response is no doubt partially governed by these influences. 
The current study further explored the nature of insulin sensitivity improvement 
following both maximal and submaximal bouts of aerobic exercise, as compared with the 
54g GC.  As we hypothesized, 30 minutes of treadmill running at 70-75% VO2max 
elicited a significant improvement in insulin sensitivity at one hour post-exercise 
(p=0.024).  This sensitization to insulin was observed to have reversed at 24 hours post-
exercise, also as hypothesized.  In addition, we hypothesized that the 54g GC would not 
elicit significant alterations in insulin sensitivity at one hour and 24 hours post-challenge; 
we were able to accept our hypotheses here, as well.  Alternatively, we rejected our 
hypothesis that maximal aerobic exercise would elicit improvements in insulin sensitivity 
one hour post-exercise, as no significant changes were observed.  It is likely that the 
maximal aerobic exercise bout did not elicit improvements in insulin sensitivity due to its 
relatively short duration (6.89 ± 0.30 mins).  Submaximal testing likely achieved 
significance through sufficient duration of exercise and energy expenditure and total 
work required to significantly improve HOMA-IR score from baseline (Bordenave et al., 
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2008; Goodyear & Kahn, 1998; Magkos et al., 2008), though Magkos et al. have 
previously noted that an approximately 900 kcal “threshold” of energy expenditure is 
necessary to elicit improvements in insulin sensitivity.  No subject achieved this 
threshold energy expenditure even during the 30-minute submaximal run (mean ± SE 
kcal expenditure, 383.12 ± 30.5), despite observed improvement in insulin sensitivity in 
our healthy cohort. 
The secondary objective of this study was to assess the relationship of plasma 
apelin with insulin sensitivity.  That our subjects were all healthy adults, each exhibiting 
HOMA-IR scores indicating normal glucose tolerance, is a limitation in assessing the 
overall relationship between apelin and insulin resistance via HOMA-IR; a potential 
“basement effect” exists herein, given that our healthy subjects may not collectively be 
able to appreciably improve their glucose tolerance and insulin sensitivity by means of 
exercise such that indirect scores (i.e. HOMA-IR) are altered and statistical significance 
achieved. A broader range of glucose tolerances may have yielded better findings, as 
would have a larger sample size.  Nevertheless, a statistically significant relationship was 
observed between resting plasma apelin concentration and HOMA-IR score at baseline 
(R=0.738, p=0.006), strengthening the notion from previous literature espousing elevated 
plasma apelin levels associated with insulin resistance (Boucher et al., 2005; Daviaud et 
al., 2006; Soriguer et al., 2009).  For a more critical assessment, we approached the 
submaximal bout of aerobic exercise as a clinical tool to evaluate apelin’s contribution 
within the framework of a stressor known to improve insulin sensitivity.  In this model, 
insulin resistance was significantly reduced (HOMA-IR scores of 2.149 vs. 1.675, ~22%) 
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one hour post-exercise, while insulin resistance was significantly correlated with plasma 
apelin concentration (R=0.672, p=0.017).  After one hour post-exercise, it is not known 
when sensitivity returned to baseline, though the relationship was reversed by 24 hours 
post-exercise in this group.  Together, these collective data suggest that elevated levels of 
plasma apelin may contribute to a greater incidence of insulin resistance or, at the very 
least, decrements in glucose tolerance within apparently healthy adult populations.  The 
significant relationship observed between plasma apelin concentration and insulin 
resistance following the submaximal aerobic exercise bout, but not the maximal, implies 
a duration-, as opposed to intensity-dependent, response, though this effect merits further 
examination.  The fact that plasma apelin concentration remained relatively unchanged 
following the submaximal bout while demonstrating a similar response to that of the 
maximal bout over time brings to question the significance of apelin’s acute contribution 
to the improvement of insulin sensitivity.  Thus, it remains at question whether apelin 
contributes to the maintenance or improvement of insulin sensitivity following acute 
exercise. 
The current study suggests that apelin, insofar as it does not respond significantly 
to acute aerobic exercise of maximal and submaximal intensities, does not significantly 
contribute to exercise-induced improvements in insulin sensitivity.  Various other factors 
may have contributed to the improvement in insulin sensitivity following sustained, 
submaximal exercise, such as NO (Roy, Perreault, & Marette, 1998), calcium and 
calmodulin/Ca2+-dependent protein kinase phosphorylation (Holloszy, 2005; Stanford & 
Goodyear, 2014), AMPK (O’Neill, 2013), hypoxia and ROS (Sandström et al., 2006), 
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phosphorylation of downstream signaling proteins, such as MAPK and Akt (Takaishi, 
Taniguchi, Takahashi, Ishikawa, & Yokoyama, 2003; Vendelbo et al., 2014) or GLUT4 
upregulation (Ren et al., 1994), though this latter factor likely does not contribute to 
enhanced glucose uptake in the immediately acute period. 
A number of limitations exist within this study, however, and prohibit a complete 
view of apelin’s relationship with insulin sensitivity.  Chief among these limitations is 
that circulating concentrations of apelin may not necessarily reflect the endogenous, local 
insulin-sensitizing activity of this adipokine.  Moreover, much like exercise itself, it 
remains uncertain on which molecular targets within the insulin and exercise-induced 
glucose uptake signaling cascades apelin exerts its effects.  Apelin has been consistently 
shown to exert its glucoregulatory effects and interact with insulin signaling via 
PI3K/Akt, though it has also been shown to induce glucose uptake in vivo and in vitro via 
eNOS activation and AMPK (Dray et al., 2008; Than et al., 2014; Zhang et al., 2014; Zhu 
et al., 2011), the latter consistently believed to be the central mediator of contraction-
induced GLUT4 translocation and glucose uptake.  To what extent these targets are 
modified during exercise remains to be fully determined (Fujii et al., 2005; Maarbjerg et 
al., 2009; Vendelbo et al., 2014).  Further, this study was limited in its scope, having 
included only apparently healthy, highly fit individuals; a greater breadth of fitness and 
body composition may have yielded interesting findings.  Performance of a true OGTT 
with an appropriate body weight-based glucose load, up to 75g, would have provided a 
better means of comparison with previous literature and, perhaps, may have elicited a 
significant response in plasma apelin.  Lastly, it may be that our study was slightly 
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underpowered as it concerns apelin (observed power 0.699); a greater sample size with 
equity amongst gender groups would have greatly enhanced our findings. 
Research remains largely equivocal in its interpretation of exercise-mediated 
improvements in glucose uptake and insulin sensitivity, particularly where it concerns the 
direct effects of exercise on improved insulin responsiveness.  The current study’s 
findings suggest that plasma apelin changes do not significantly contribute to the 
transient improvement in insulin sensitivity following acute aerobic exercise, in our 
healthy cohort.  Likely, apelin requires a greater stimulus for significant response or that 
some energy deficit threshold or otherwise significant disruption to glucose homeostasis 
must be met, such as the previously outlined threshold suggested by Magkos et al. 
(2008). 
 The specific responses of insulin-sensitive tissues (i.e. skeletal muscle, adipose 
tissue, liver) to apelin during exercise also merit examination.  Results from the current 
study allow the authors to conclude that acute aerobic exercise of both maximal and 70-
75% VO2max submaximal intensities does not elicit significant alterations in plasma 
apelin at the times measured.  GC, as well, elicited no significant alteration in plasma 
apelin at the times measured.  Despite this, the profiles of apelin’s response over time, as 
it pertains to exercise versus GC, suggest disparate trends. Furthermore, there may exist 
an aerobic exercise duration-dependent effect on the metabolic input of apelin and its 
supposed role on insulin sensitivity improvement, though the measure of whole body 
insulin resistance via HOMA-IR index renders our results and interpretations ultimately 
incomplete.  The significant relationships observed between plasma apelin concentration 
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and insulin resistance both at rest and following the 30-minute acute bout of aerobic 
exercise may well serve as preliminary evidence of apelin’s importance regarding acute 
contribution to glucose homeostasis and insulin sensitivity.  The improvement of insulin 
sensitivity following a single bout of exercise is undoubtedly a multifaceted process, 
involving a number of key proteins and GLUT4 regulators.  Further elucidation of 
apelin’s role in this regard is relevant and necessary, despite the current study’s findings.   
Downstream effector proteins thought to unite insulin- and exercise-mediated GLUT4 
transport and glucose uptake – purported to be TBC1D (or AS160) and Rab proteins – 
must also be further examined through the lens of apelin and exercise response. 
Summary and Future Directions 
 Our study has clearly demonstrated that, because no alterations in plasma apelin 
were observed in any of the three conditions, circulating plasma apelin seems not to be 
an obligatory regulator of glucose homeostasis or insulin sensitivity, despite each 
condition effecting known and anticipated alterations in blood glucose and plasma 
insulin.  Future studies should tease apart the exercise-mediated and postprandial apelin 
trends, however, as this may reveal interesting findings regarding exercise-mediated 
versus postprandial apelin profiles.  For future investigation, it is imperative that a larger 
and more varied subject pool be utilized so as to increase power as well as enhance our 
ability to determine plasma apelin’s relationship with potential predictors, such as body 
fat percentage, region of adiposity, fitness level, glucose tolerance, etc.  Additionally, a 
greater appreciation for the effects of exercise on plasma apelin may be gained with more 
frequent blood draws, as previously mentioned, so as to obtain a working profile of this 
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important adipokine and how it may affect insulin sensitivity; a profile of up to six hours 
post-intervention or exercise – with regular blood draws therein – should be examined.  
As our study ensured, it is essential to consider the effects of hydration and/or certain 
pharmaceuticals (i.e. ACE inhibitors) on blood pressure and fluid regulation and resulting 
apelin alterations, as well as appropriate storage and preparation of plasma samples with 
protease inhibitors when appropriate, as some previous studies have failed to report.  
Lastly, future efforts must focus on cell- and tissue-specific responses to exercise in 
animal and human models, with specific focus on apelin’s receptor, APJ. 
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APPENDIX A 
AHA/ACSM HEALTH/FITNESS FACILITY PRE-PARTICIPATION SCREENING 
QUESTIONNAIRE 
 
 
Assess your health status by marking all true statements 
 
History: 
 
You have had: 
 
__________________ a heart attack 
__________________ heart surgery 
__________________ cardiac catheterization coronary 
__________________ angioplasty (PTCA) 
__________________ Pacemaker/implantable cardiac defibrillator 
__________________ rhythm disturbance 
__________________ heart valve disease 
__________________ heart failure 
__________________ heart transplantation 
__________________ congenital heart disease  
 
Symptoms: 
 
_________________ You experience chest discomfort with exertion 
_________________ You experience unreasonable breathlessness 
 _________________You experience dizziness, fainting, or blackouts 
_________________ You take heart medications  
 
Other health issues: 
 
________________ You have diabetes 
________________ You have asthma or other lung disease 
________________ You have burning or cramping sensation in your lower legs when 
walking short distances 
________________ You have musculoskeletal problems that limit your physical activity 
________________ You have concerns about the safety of exercise 
________________ You take prescription medication(s) 
________________ You are pregnant  
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If you marked any of these statements in this section, consult you physician or other 
appropriate health care provider before engaging in exercise. You may need to use a 
facility with a medically qualified staff. 
 
Cardiovascular risk factor: 
 
___________________ You are a man older than 45 years 
___________________ You are a woman older than 55 years, have had a hysterectomy, 
or are postmenopausal 
___________________ You smoke, or quit smoking within the previous 6 month 
___________________ Your blood pressure is >140/90 mm Hg 
___________________ You do not know your blood pressure 
___________________ You take blood pressure medication 
___________________ Your blood cholesterol level is > 200 mg/dl 
___________________ You do not know your cholesterol level  
___________________ You have a close blood relative who had a heart attack or heart 
surgery before age 55 (father or brother) or age 65 (mother or sister)  
___________________ You are physically inactive (i.e., you get <30 minutes of physical 
activity on at least 3 per week)  
___________________ You are >20 pounds overweight  
 
If you marked two or more of the statements in this section you should consult your 
physician or other appropriate health care provider before engaging in exercise. 
You will benefit from using our facility with a professionally qualified exercise staff 
to guide your exercise program. 
 
___________________ None of the above  
 
You should be able to exercise safely without consulting your physician or other 
appropriate health care provider in a self-guided program or almost any facility 
including our facility that meets your exercise program needs. 
 
Modified from American College of Sports Medicine and American Heart Association. 
ACSM/AHA Joint Position Statement: Recommendations for cardiovascular screening, 
staffing, and emergency policies at health/fitness facilities. Medicine and Science in 
Sports and Exercise 1998: 1018  
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APPENDIX B 
HEALTH HISTORY, DRUG USAGE, AND FITNESS ACTIVITY QUESTIONNAIRE 
 
 
Subject:        
ID:          
      
 
Health History 
 
Do you have any musculoskeletal illnesses or injuries that would restrict your 
participation in either a maximal or submaximal exercise bout (as performed on a 
treadmill or with use of free weights while performing a squatting motion)?   
    
        YES                               NO                            
If yes, please describe.         
  
             
   
 
Have you ever been diagnosed with cardiovascular disorders (heart problems, high blood 
pressure, high cholesterol, etc.)?    YES                   NO                            
If yes, please describe.         
  
             
  
 
Have you ever been diagnosed with metabolic disorders (diabetes, etc.)? 
        YES                               NO                            
If yes, please describe.         
  
             
  
 
Could you currently be pregnant?   YES                             NO     N/A                              
 
Please list any major illnesses, hospitalizations, or surgical procedures within the last two 
years. 
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Drug/Supplement Usage 
 
Are you a current smoker/Tobacco user?  YES                             NO 
 
Have you every smoked/tobacco use in the past?      YES                             NO    
If yes, please describe history.         
             
 
Are you currently taking any medication(s)?  YES                             NO                                
 
If yes, please list name of medication(s), reason for and length of administration. 
             
 __________________________________________________________________ 
 
Are you currently taking any nutritional/vitamin supplements?   
        YES                             NO                                
 
If yes, please list name of supplement, reason for and length of administration. 
              
 
Are you taking energy bars or drinks on a routine basis? YES  NO 
 
Fitness Activity       
 
Please describe your current participation in the following types of exercise: 
 
1. Aerobic (aerobic classes, walking, jogging, stair climbing, hiking, cycling, running 
swimming etc.)  If more than one activity please list separately. 
 
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in the aerobic activity described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:           
            
 __________________________________________________________________ 
 
2. Anaerobic (weight training, sprinting, boxing, martial arts, interval training,  etc.) 
 
Frequency (# of days per week):     
	  97	  
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in anaerobic activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:          
  
            
  
 
3. Organized or Recreational sports (basketball, soccer, lacrosse, etc.) 
 
Type of sport(s):          
             
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in sports activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:           
             
 
4.  Other activities 
 
Type of activities (Thai chi, yoga, stretching activities,  
Classification (to be assessed by researchers—leave blank) 
Need to confirm aerobic capacity by maximal oxygen uptake test. 
 
 
Trained  Untrained 
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APPENDIX C 
UNIVERSITY OF NORTH CAROLINA AT GREENSBORO 
CONSENT TO ACT AS A HUMAN PARTICIPANT 
 
 
Project Title: Acute effects of exercise on apelin, glucose, insulin and insulin sensitivity 
in apparently healthy individuals 
 
Principal Investigator and Faculty Advisor (if applicable): Justin Waller (PI) and Dr. 
Allan Goldfarb 
 
Participant's Name: ________ 
 
What is the study about? 
 
This is a research project. Your participation is voluntary. Your fat cells send signals to 
other tissues and one of these is known as apelin. The amount of fat you have influences 
blood apelin level and alters glucose balance and insulin sensitivity. Exercise serves as an 
excellent model to alter blood glucose levels and enhance insulin sensitivity. Apelin’s 
role on insulin sensitivity and glucose balance in response to acute exercise has not been 
investigated. We intend to determine how moderate and high intensity acute aerobic 
exercise influence blood apelin level, along with blood insulin and blood glucose. It is the 
purpose of this study to see if apelin levels in the blood change to either a high intensity 
aerobic exercise known to enhance blood glucose levels compared to a moderate intensity 
exercise known to maintain blood glucose levels. 
 
Why are you asking me? 
 
You are being asked to participate in this study because little research has been done 
regarding apelin and its effects on glucose homeostasis and insulin sensitivity in 
apparently healthy human subjects. You also fit our criteria of being between the ages of 
18-35. Prior to your participation, you will complete an American Heart 
Association/American College of Sports Medicine health fitness facility pre-participation 
screening questionnaire and a physical activity form. This is done in order to screen out 
individuals who may have musculoskeletal, cardiovascular or metabolic disorders that 
may interfere with the testing procedures or the measurements obtained, or women who 
may be pregnant or breast feeding. Only volunteers that do not use tobacco products 
(minimum 6 months) may be enrolled. Also, if you have been on any antioxidant 
supplement you must discontinue use for at least two weeks prior to being accepted as a 
subject. If you are taking any medication or drugs that may influence glucose, insulin or 
your metabolism/inflammation you will not be allowed to participate in this study. If your 
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resting fasting blood glucose is above 100 mg/dl you will be excluded. If your resting 
blood pressure is elevated (140/90 mmHg) you will also be excluded from participating. 
 
What will you ask me to do if I agree to be in the study? 
 
You will be asked to participate in this study through six (6) visits to our laboratory. Two 
of these visits will involve exercise and blood sampling. Another visit will involve 
ingestion of a glucose gel and blood sampling and three visits will only involve blood 
sampling. 
 
VISIT 1: You will be pre-screened for the information provided in the preceding section 
of this consent form. Screening will occur on the morning of your first visit. You will 
also bring a 3-day food record on your first visit listing amounts of food and drink. The 
time for this screening should be no longer than 15 minutes. 
 
After screening you will have your height, weight, blood pressure and body fat 
percentage (using a skinfold caliper at seven sites) determined. A resting blood sample 
from an arm vein will then be obtained (approximately 3 teaspoons, or 14 mls); you may 
feel slight discomfort or pain with the needle stick. You will then perform a graded 
treadmill run to determine your aerobic capacity (VO2max). The grade and speed of the 
treadmill will be increased gradually over time as you breathe through a mouthpiece 
connected to a tube to enable expired air samples to be measured for oxygen content. The 
test will continue until your aerobic capacity is reached or you indicate you can no longer 
maintain the pace or want to stop; you may feel some discomfort/fatigue during this test. 
There are bars on either side of the treadmill to grasp if needed. You will then be given a 
one-minute cool down/walk, after which another blood sample (3 teaspoons) will be 
obtained. Another resting, fasted blood sample (3 teaspoons) will be obtained 60 minutes 
after exercise. You will be provided water throughout this visit. You will press on the 
needle stick area for 2-5 minutes to avoid bruising after each of these blood samples is 
taken. The total time for this part of the visit will be no more than 1 hour and 45 
minutes. 
 
VISIT 2: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
VISIT 3: You will return to the lab at least 7 days after the initial graded run in the 
morning (same time and condition) to perform either a 30-minute run at a moderate 
intensity (75% of your aerobic capacity) or ingest a glucose gel about 50 grams). Your 
weight, blood pressure and resting heart rate will be determined as before. You will have 
blood taken at rest (3 teaspoons at each time point), immediately post-exercise (or gel 
consumption) and 60 minutes post-exercise (or gel consumption). Your heart rate and 
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oxygen consumption will be monitored every 5 minutes during the run or after the 
ingestion of the gel. You will also give us feedback as to the difficulty of the exercise. 
You will be given water throughout this visit. You will also bring a 3-day food record 
prior to the third visit. The total time for this visit will be no more than 2 hours. 
 
VISIT 4: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
VISIT 5: You will return to the lab at least 7 days after visit 3 in the morning (same time 
and condition) to perform the treatment you did not complete in visit 3. Your weight, 
blood pressure and resting heart rate will be determined as before. You will have blood 
taken at rest (3 teaspoons at each time point)), immediately post-exercise (or gel 
consumption) and 60 minutes post-exercise (or gel consumption). Your heart rate and 
oxygen consumption will be monitored every 5 minutes during the run or after the 
ingestion of the gel. You will also give us feedback as to the difficulty of the exercise. 
You will be given water throughout this visit. You will also bring a 3-day food record 
prior to the third visit. The total time for this visit will be no more than 2 hours. 
 
VISIT 6: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
This will conclude your study participation. Total participation time will be about 6.75 
hours. 
 
All information concerning your records will be kept confidential and you will not be 
identified in any presentation or published work. 
 
In addition, all blood samples obtained will be kept for possible future analyses and 
research, though you will not be identified in any way. 
 
You may contact the PI, Justin Waller, at jdwaller@uncg.edu or (336) 613-6899 or Dr. 
Allan Goldfarb at ahgoldfa@uncg.edu or (336) 334-3029 with any questions concerning 
the nature of your participation and your consent to participate in this research project. 
 
What are the risks to me? 
 
The specific risks associated with participation in this research project are listed below. 
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You may feel tired and out of breath after the maximum aerobic capacity test which is 
normal. There is a very small risk of death as a result of this test (< 0.01%) and this is for 
all age groups and includes individuals that might have health problems. Since you are 
young and do not have any known health problems the risks associated with this test are 
reduced. You may let the researcher know if you are experiencing discomfort during the 
maximum aerobic capacity test, at which time the test will be discontinued. You may feel 
tired after the 30 minute run, which is normal. 
 
It is possible that you may feel some symptoms of low blood sugar during either of the 
exercise sessions. Some of these symptoms are: 
 
• Shakiness or hand tremors  
• Ringing in the ears  
• Chills or clamminess  
• Lightheadedness or dizziness  
• Irritability  
• Nausea 
 
In the event that you feel these symptoms, you should immediately inform the researcher 
so that he/she may discontinue the test. To reduce the risk to you, a safety ‘spotter’ will 
be in place at all times during the testing period to assist you. 
 
Sterile techniques will be utilized to take the blood and there may be a small sensation of 
pain associated with taking blood. There may be some slight bruising associated with the 
blood sampling; placing direct pressure over the area where the blood was taken will 
minimize this. You must realize that infection can occur with any type of blood drawing 
but following sterile techniques will reduce this risk. 
 
If you have questions, want more information or have suggestions, please contact: Justin 
Waller at jdwaller@uncg.edu or (336) 613-6899 or Dr. Allan Goldfarb at (336) 334-3029 
or ahgoldfa@uncg.edu. 
 
If you have any concerns about your rights, how you are being treated, concerns or 
complaints about this project or benefits or risks associated with being in this study, 
please contact the Office of Research Integrity at UNCG toll-free at (855)-251-2351. 
 
What happens if I am injured during this study? 
 
UNCG is not able to offer financial compensation nor to absorb the costs of medical 
treatment should you be inured as a result of participating in this research study. 
However, we will provide a referral to your primary care physician. 
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Are there any benefits to society as a result of me taking part in this research? 
 
This research project may advance the exercise science literature. Apelin has recently 
been reported to influence insulin sensitivity and glucose regulation, which carries 
important implications for the treatment of diabetes. Findings from this research project 
may advance future research in this area. 
 
Are there any benefits to me for taking part in this research study? 
 
Through your participation in this study, you will learn of your maximal aerobic capacity, 
percent body fat and blood pressure. Additionally, you will be able to receive information 
on how you responded to the exercise sessions. You can ask for the blood glucose data to 
see if you maintained blood glucose balance on the 30 minute run. This information may 
be important in improving your overall health, and may serve as baseline data related to 
these measures. Otherwise, the information gathered in this study may not directly benefit 
you; however, it may advance the exercise science literature. 
 
Will I get paid for being in the study? Will it cost me anything? 
 
There are no costs to you or payments made to you for participating in this study. 
 
How will you keep my information confidential? 
 
All information concerning your records and obtained data will be kept confidential and 
you will not be identified in any presentation or published work. You will receive a study 
number, which will not be linked to your name. All records and data related to you, 
specifically, will be de-identified and coded and will be safely kept in a locked file 
cabinet. The master list for this study will also be codified with no identifying 
information. All study data will be destroyed, via document shredding and file erasure, 
upon publishing of the research data. This consent form will be kept for three years as 
required by federal law, after which time they will be destroyed to protect your identity. 
Blood samples will be properly disposed of after manuscripts have been published in 
accordance with biological hazard codes. All information obtained in this study is strictly 
confidential unless disclosure is required by law. 
 
What if I want to leave the study? 
 
You have the right to refuse to participate or to withdraw at any time, without penalty. If 
you do withdraw, it will not affect you in any way. If you choose to withdraw, you may 
request that any of your data which has been collected be destroyed unless it is in a de-
identifiable state. 
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What about new information/changes in the study? 
 
If significant new information relating to the study becomes available which may relate 
to your willingness to continue to participate, this information will be provided to you. 
 
Voluntary Consent by Participant: 
 
By signing this consent form/completing this survey/activity (used for an IRB-approved 
waiver of signature) you are agreeing that you read, or it has been read to you, and you 
fully understand the contents of this document and are openly willing consent to take part 
in this study. All of your questions concerning this study have been answered. By signing 
this form, you are agreeing that you are 18 years of age or older and are agreeing to 
participate, or have the individual specified above as a participant participate, in this 
study described to you by either Justin Waller or Dr. Allan Goldfarb. 
 
Signature: ________________________ Date: ________________ 
